

# CURRICULUM VITAE

---

## **Roger Olofsson Bagge MD, PhD**

Professor, Senior Consultant surgeon, Research group leader  
Department of Breast and Melanoma Surgery, Sahlgrenska University Hospital  
Sahlgrenska Center for Cancer Research, Gothenburg University  
Wallenberg Centre for Molecular and Translational Medicine, Gothenburg University

Address: Department of Surgery  
Sahlgrenska University Hospital  
413 45 Gothenburg  
Sweden  
Email: roger.olofsson.bagge@gu.se  
Phone: +46 70 7462119  
Citizenship: Swedish  
Birth date: 1978-FEB-12  
Languages: Complete fluency in Swedish and English at professional and academic levels.

---

## **FORMAL EDUCATION**

---

2015 Visiting Scholarship in Melanoma Surgery, Professor Jonathan Zager, Lee Moffitt Cancer Center, Tampa, Florida, USA  
2012 Specialist certificate in Surgery (Consultant Surgeon), Swedish National Board of Health and Welfare, Sweden.  
2006 Licensed physician, Swedish National Board of Health and Welfare, Sweden.  
2004 University Medical Degree (MD). The Sahlgrenska Academy at University of Gothenburg, Sweden.

---

## **CLINICAL APPOINTMENTS AND ASSIGNMENTS**

---

2026- Scientific Advisor in General Surgery, Swedish National Board of Health and Welfare, Sweden  
2026- Vice Head (Research) of Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg.  
2025 Inaugural Cutaneous Oncology Regional Therapies Visiting Professor, H. Lee Moffitt Comprehensive Cancer Center and Research Institute, Tampa, Florida, USA.  
2023-present University Senior Consultant Surgeon, Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden  
2022-present Professor in Cancer Surgery, Sahlgrenska Academy at Gothenburg University  
2022-present Board Member for Sahlgrenska Comprehensive Cancer Center (SCCC), Sahlgrenska University Hospital, Gothenburg, Sweden  
2018-2021 Director, Sahlgrenska Breast Center, Sahlgrenska University Hospital  
2017-2019 Member of a group introducing new surgical techniques at the newly built Imaging and Interventioncenter "Bild och Interventionscentrum" at Sahlgrenska University Hospital.  
2016-present Senior Consultant Surgeon, Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden  
2016-2022 Associate professor in Surgery, Sahlgrenska Academy at Gothenburg University  
2015-present Competent as senior on-call surgeon (bakjour)  
2015-2021 Head, Breast and Melanoma Surgery, Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden  
2013-2015 Consultant Surgeon, Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden

2006-2012	Resident in Surgery, Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden
2006-2006	Internship, Transplantation and Liver surgery, The Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden
2004-2006	Internship, Norra Älvsborg County Hospital, Trollhättan, Sweden

---

### HIGHER EDUCATION

---

2015	Visiting scholarship (2 months), Professor Jonathan Zager, Lee Moffitt Cancer Center, Tampa, Florida, USA
2013	Doctor of Medicine, PhD. Isolated regional perfusion for metastases of malignant melanoma – Clinical and experimental studies. The Sahlgrenska Academy at Göteborg University, Sweden. Supervisors: Per Lindnér and Jan Mattsson
2000-2004	University Medical Degree (MD). The Sahlgrenska Academy at Göteborg University, Sweden.
2000	Introduction to Research, part II. Dept. of Physiology, Institution of Physiology and Pharmacology, the Sahlgrenska Academy at Göteborg University, Sweden.
1999	Introduction to Research, part I. Dept. of Physiology, Institution of Physiology and Pharmacology, the Sahlgrenska Academy at Göteborg University, Sweden.
1999	Cell biology. Sahlgrenska Academy at Göteborg University, Sweden.

---

### MEMBERSHIP OF PROFESSIONAL ASSOCIATIONS

---

2025-	European Surgical Association (ESA)
2023-	International Surgery Group (ISG)
2021-	European Society of Medical Oncology (ESMO)
2020-	American Association of Clinical Oncology (ASCO)
2018-	European Society of Surgical Oncology (ESSO)

---

### PUBLISHED SCIENTIFIC WORK

---

#### BIBLIOMETRICS

ORCID: 0000-0001-5795-0355

Scopus ID: 56341131700

Roger Olofsson Bagge has a h-index of 27 on WebOfScience (based on 215 publications), 2728 citations (excluding self-citations) with an average of 13.1 citations per publication. 18 first author publications and 55 publications as senior author.

#### ORIGINAL WORK

1. Nelson A, Alghaib S, Björkström K, Isaksson K, Krabbe E, Orme S, Kadefors M, Wallander M, Bjursten S, Ullenhag GJ, Carneiro A, Helgadottir H, Ny L, **Olofsson Bagge R**. Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study. *Eur J Cancer*. 2026 May 23;243:116833.
2. D Arrigo D, Park KS, Lässer C, Sigalas GP, Symonds E, Urzi O, Locatelli C, **Olofsson Bagge R**, Lötvall J, Crescitelli R. Frozen melanoma tissues yield extracellular vesicles with preserved diagnostic and immunogenic properties. *BMC Med*. 2026 May 21.
3. Nelson A, Riise R, Alsén S, Wong A, Carlson P, Edman S, Holgersson J, **Olofsson Bagge R**, Johansson I, Sadik M, Edenbrandt L, Nilsson LM, Nilsson JA, Ny L. Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial). *J Immunother Cancer*. 2026 Mar 18;14(3):e014401.

4. Ejder P, Jespersen H, Hernberg M, Ny L, Carneiro A, Ellegård S, Mattila K, **Olofsson Bagge R**, Fountoukidis G, Brandberg Y, Mandala M, O Carrigan B, Schilling B, Aranche A, Hamid O, Berglund A, Helgadottir H, Ullenhag G. Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma. *BMC Cancer*. 2026 Mar 27;26(1):460.
5. Patel AAH, Dzanan JJ, Ali KX, Eklund EA, Alvarez SW, Raj D, Dankis M, Altinönder I, Schwarz M, Le Gal K, Bedel E, El Zowalaty AE, Jonasson E, Albatrok H, Gul N, Bossowski JP, Pillai R, Micke P, Botling J, Akyürek LM, Angeletti D, Sayin SI, Härtlova A, Papagiannakopoulos T, **Olofsson Bagge R**, Ståhlberg A, Hallqvist A, Wiel C, Sayin VI. Ageing promotes metastasis via activation of the integrated stress response. *Nature*. 2026 Mar 11.
6. Zulfaj E, Nejat A, Kalani M, Miljanovic A, Ekström K, Crescitelli R, Elmahdy A, Thorsell A, **Olofsson Bagge R**, Redfors B, Omerovic E. Proteomic analysis of tissue-derived extracellular vesicles shows region-specific molecular changes in a rat model of takotsubo syndrome. *Sci Rep*. 2026 Mar 10;16(1):8731. doi: 10.1038/s41598-026-42812-5. PMID: 41807579; PMCID: PMC12979827.
7. Ny L, **Olofsson Bagge R**. New directions in combination treatment of uveal melanoma with liver metastases. *Lancet Oncol*. 2026 Mar;27(3):273-275. doi: 10.1016/S1470-2045(26)00002-1. PMID: 41785889.
8. Mor E, Apte S, Bressel M, Broman KK, Hieken TJ, **Olofsson Bagge R**, Berman RS, Lee AY, Kuijpers AM, Ollila DW, van Akkooi ACJ, Zager JS, Gyorki DE. Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients with Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial. *Ann Surg Oncol*. 2026 Feb 26. doi: 10.1245/s10434-026-19260-6. Epub ahead of print. PMID: 41746574.
9. Alkner S, Appelgren M, Szulkin R, Wieslander E, Rogowski V, Gustafsson CJ, Nissen HD, Sackey H, Lundstedt D, Andersson Y, Bergkvist L, Frisell J, **Olofsson Bagge R**, Sund M, Rydén L, Offersen BV, de Boniface J. Association between shoulder joint radiation dose and arm morbidity in the randomized breast cancer trial SENOMAC. *Radiother Oncol*. 2026 Feb 21;218:111454. doi: 10.1016/j.radonc.2026.111454. Epub ahead of print. PMID: 41730479.
10. Helgadottir H, Carneiro A, Portelli F, Papadakis K, Björkström K, Yang M, Johansson I, Skogvall Svensson I, Jazrawi A, Hallgren A, Harbst K, Bark R, Egyhazi Brage S, Berglund A, Isaksson K, Wickström S, Nilsson J, Ny L, Jönsson G, **Olofsson Bagge R**; SWE-NEO Study Group. SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial. *Acta Oncol*. 2026 Feb 19;65:126-130.
11. Constantinescu A, **Olofsson Bagge R**, Huibers A. Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis. *Eur J Surg Oncol*. 2026 Jan 23;52(3):111424. doi: 10.1016/j.ejso.2026.111424. Epub ahead of print. PMID: 41616426.
12. Riaz N, Leong SP, Kashani-Sabet M, White RL Jr, Vetto JT, Schneebaum S, O'Donoghue C, Howard JH, Avisar E, Namm JP, Kosiorek H, Pockaj B, Faries M, Karakousis G, Zager JS, **Olofsson Bagge R**. Prognostic Value of Non-nodal Regional Metastases in Predicting Sentinel Lymph Node Status in Cutaneous Melanoma: Multicenter Analysis of the Sentinel Lymph Node Working Group Database. *Ann Surg Oncol*. 2026 Jan 23. doi: 10.1245/s10434-026-19086-2. Epub ahead of print. PMID: 41578083.
13. Pistiolis L, Litsne H, **Olofsson Bagge R**, Axelsson KF. Visual Impairment and Cancer Risk: A Nationwide Cohort Study of Adult Swedish Men and Women. *Cancers (Basel)*. 2025 Dec 31;18(1):147. doi: 10.3390/cancers18010147. PMID: 41514655; PMCID: PMC12784979.
14. Ekström K, Riaz N, Larsson K, Nemeth A, Crescitelli R, Linderholm B, **Olofsson Bagge R**. Plasma extracellular vesicles reflect response and prognosis in patients with breast cancer undergoing neoadjuvant treatment. *Breast Cancer Res*. 2026 Jan 9;28(1):22. doi: 10.1186/s13058-025-02209-0. PMID: 41514466; PMCID: PMC12849309.
15. Helgadottir H, Ny L, Ullenhag GJ, Mikiver R, Isaksson K, **Olofsson Bagge R**. Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study. *Eur J Cancer*. 2026 Feb 5;234:116201. doi: 10.1016/j.ejca.2025.116201. Epub 2025 Dec 26. PMID: 41500895.

16. Kadefors M, Nelson A, Blomberg E, Ståhlberg A, Ny L, **Olofsson Bagge R**. Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab. *Immuno-oncol Technol*. 2025 Oct 26;28:101079.
17. Yu L, Ding T, **Olofsson Bagge R**, Zheng L, Hao X. Proteomics of Prostate Cancer Tissue Small Extracellular Vesicles Reveal Alteration of Metabolism. *Proteomics*. 2025 Nov 17:e70081.
18. Mirzaei N, Wärnberg F, Zaar P, Oliveira Diniz M, Karakatsanis A, Leonhardt H, **Olofsson Bagge R**. Impact of an ultra-low dose of superparamagnetic iron oxide on postoperative breast MRI artifacts and skin discoloration in patients with breast cancer. *Scand J Surg*. 2025 Nov 12:14574969251387495.
19. Ladjevardi CO, Naeser Y, Dyrke U, Papantoniou D, **Olofsson Bagge R**, Elander N, Ingvar C, Flygare P, Nilsson C, Jakobsson F, Lange-Norström K, Sundin A, Berglund A, Nyberg F, Ahringberg-Kald B, Helgadottir H, Ullenhag G. Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden. *Lancet Oncol*. 2025 Nov;26(11):1501-1510.
20. Yu WY, Pazhava A, Weitemeyer MB, Hölmich LR, Johansson I, **Olofsson Bagge R**, Utikal J, Venna S, Jackson J, Amaral T, van Akkooi A, Kolodney MS, McArthur GA, Meves A. CP-GEP Identifies High-Risk T1a Melanoma Patients Beyond Established Adverse Features. *J Am Acad Dermatol*. 2025 Oct 13:S0190-9622(25)03004-X.
21. Lindqvist Bagge AS, **Olofsson Bagge R**, Carlander A. Normative Data for the Swedish Versions of the Beck Anxiety Index and Beck Depression Inventory-Version 2. *Int J Methods Psychiatr Res*. 2025 Sep;34(3):e70024.
22. Alonso-Agudo T, Johansson J, Ståhlberg A, **Olofsson Bagge R**. Cellular and molecular characterization of  $\gamma\delta$  T cells in peripheral blood from patients with metastases from cutaneous and uveal melanoma. *Front Immunol*. 2025 Jul 28;16:1564333.
23. Sundh L, Alzoubi M, Abu-Oddos N, Båtelsson S, Nyman P, Karakatsanis A, Eriksson S, Ravichandran M, Chin K, **Olofsson Bagge R**, Mirzaei N, Wärnberg F. Ultra-low dose superparamagnetic iron oxide nanoparticle injection for sentinel lymph node detection in breast cancer: prospective cohort study. *Br J Surg*. 2025 Jul 3;112(7)
24. Nelson A, Krabbe E, Björkström K, Huibers A, Jovanovic B, Blank CU, Ullenhag GJ, Helgadottir H, Ny L, **Olofsson Bagge R**. Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL). *Eur J Cancer*. 2025 Jun 25;224:115485.
25. Dugan MM, Bobby A, Ghali H, Aflatoon S, DePalo DK, Huibers A, Fan W, **Olofsson Bagge R**, Zager JS. Isolated Limb Infusion or Perfusion as First-Line Versus Second-Line Therapy for In-Transit Metastatic Melanoma. *Ann Surg Oncol*. 2025 May 10.
26. Pistiolis L, Alawieh S, Halldorsdottir T, Kovács A, **Olofsson Bagge R**. Melatonin MT1 Receptor Expression in Luminal Invasive Ductal Breast Carcinoma in Postmenopausal Women. *Biomolecules*. 2025 Apr 15;15(4):581.
27. Stassen RC, Maas CCHM, Leong SP, Kashani-Sabet M, White RL, Pockaj BA, Zager JS, Schneebaum S, Vetto JT, Avisar E, Harrison Howard J, O'Donoghue C, Kosiorek H, van Akkooi ACJ, Verhoef C, van Klaveren D, Grünhagen DJ, **Olofsson Bagge R**. External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy. *Br J Surg*. 2025 Mar 28;112(4):znaf037.
28. Fager A, Samuelsson M, **Olofsson Bagge R**, Pivodic A, Bjursten S, Levin M, Jespersen H, Ny L. Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastases. *BJC Rep*. 2025 Apr 11;3(1):22.
29. Lo SN, Gjorup C, Chakera AH, Hölmich LR, Moncrieff M, MacKenzie Ross A, Cassell O, Ma J, Weitemeyer MB, **Olofsson Bagge R**, Klausen S, Calsavara VF, Duprat Neto JP, Bertolli E, Ch'ng S, Saw RPM, Shannon KF, Spillane AJ, Nieweg OE, Stretch JR, Mann GJ, Geh JLC, Haydu LE, Martin RCW, Sharon C, Karakousis GC, Kashani-Sabet M, Adigbli G, El Sharouni MA, Gershenwald JE, Scolyer RA, Thompson JF, Varey AHR. Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma. *JAMA Dermatol*. 2025 Apr 9.
30. Wennberg E, Claeson M, **Olofsson Bagge R**, Polesie S, Paoli J. Wise or wide (WoW) study protocol: a national, multicentre, prospective, randomised and controlled, parallel group, non-

- inferiority study to compare single-staged versus two-staged excisions of thin invasive ( $\leq 1.0$  mm) melanoma. *BMJ Open*. 2025 Apr 2;15(4):e094544.
31. Huibers A, Leong SP, Kashani-Sabet M, White RL Jr, Vetto J, Schneebaum S, O'Donoghue C, Howard H, Avisar E, Namm JP, Kosiorek H, Faries M, Karakousis G, Zager JS, **Olofsson Bagge R**; on behalf of the Sentinel Lymph Node Working Group. Identification of Predictive Factors for the Development of In-Transit Metastasis in Patients with Melanoma. *Ann Surg Oncol*. 2025 Mar 10.
  32. Huibers A, Wong A, Krabbe E, Carlson P, **Olofsson Bagge R**. Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity. *J Vis Exp*. 2025 Jan 31;(215).
  33. Morrison SL, Han G, Elenwa F, Leong SP, Kashani-Sabet M, Pockaj B, Kosiorek HE, White RL Jr, Zager JS, Messina JL, Sondak V, O'Donoghue C, Howard JH, Schneebaum S, **Olofsson Bagge R**, Namm JP, Garberoglio C, Avisar E, Fowler G, Han D, Vetto J; Sentinel Lymph Node Working Group. Tumor infiltrating lymphocytes in primary melanoma are associated with a better prognosis. *Am J Surg*. 2025 Feb 8:116243.
  34. Riaz N, Huibers A, Leong SP, Kashani-Sabet M, White RL Jr, Vetto JT, Schneebaum S, O'Donoghue C, Howard H, Avisar E, Namm JP, Kosiorek H, Pockaj B, Faries M, Karakousis G, Zager JS, **Olofsson Bagge R**. Prognostic Value of Nevus-Associated Melanoma in Patients with Melanoma. *Ann Surg Oncol*. 2025 Feb 1. doi: 10.1245/s10434-025-16945-2. Epub ahead of print. PMID: 39893342.
  35. Christenhusz A, Mirzaei N, Karakatsanis A, Eriksson S, Wärnberg F, **Olofsson Bagge R**, van der Palen J, Simanowski J, Salamzadeh S, Ten Haken B, Dassen AE, Alic L. Magnetic Sentinel Lymph Node Biopsy in Early Breast Cancer Patients: An Individual Patient Data Meta-analysis of Tracer Uptake. *Ann Surg Oncol*. 2024 Dec 17.
  36. Zaar P, Mirzaei N, Jalnefjord O, de Coursey E, Johansson I, Wärnberg F, Leonhardt H, **Olofsson Bagge R**. Development of an optimized MRI protocol for a rapid preoperative identification of sentinel lymph nodes using superparamagnetic iron oxide - The Gothenburg fast acquisition sentinel lymph node tracking magnetic resonance imaging protocol (GO-FAST-MRI). *Eur J Surg Oncol*. 2025 Jan;51(1):109362. doi: 10.1016/j.ejso.2024.109362.
  37. DePalo DK, Dugan MM, Naqvi SMH, Ollila DW, Hieken TJ, Block MS, van Houdt WJ, Wouters MWJM, Reijers SJM, Asher N, Broman KK, Duncan Z, Anderson M, Gyorki DE, Snow H, Held J, Farma JM, Vetto JT, Hui JYC, Kolbow M, Saw RPM, Lo SN, Long GV, Thompson JF, Kim Y, Karapetyan L, Ny L, van Akkooi ACJ, **Olofsson Bagge R**, Zager JS. A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases. *Cancer*. 2024 Nov 10.
  38. Tvedskov TF, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, **Olofsson Bagge R**, Reimer T, Sund M, Rydén L, Christiansen P, de Boniface J; SENOMAC Trialists' Group. Axillary clearance and chemotherapy rates in ER+HER2- breast cancer: secondary analysis of the SENOMAC trial. *Lancet Reg Health Eur*. 2024 Sep 26;47:101083.
  39. Skarping I, Bendahl PO, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Christiansen P, Filtenborg Tvedskov T, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Vrou Offersen B, **Olofsson Bagge R**, Reimer T, Sund M, Rydén L, de Boniface J. Prediction of High Nodal Burden in Patients With Sentinel Node-Positive Luminal ERBB2-Negative Breast Cancer. *JAMA Surg*. 2024 Sep 25:e243944.
  40. Karlsson JW, Sah VR, **Olofsson Bagge R**, Kuznetsova I, Iqba M, Alsen S, Stenqvist S, Saxena A, Ny L, Nilsson LM, Nilsson JA. Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases. *Elife*. 2024 Sep 23;12:RP91705.
  41. Keiller AC, Axelsson M, Bragadottir G, Lannemyr L, Wijk J, Blennow K, Zetterberg H, **Olofsson Bagge R**. Standard versus High Cardiopulmonary Bypass Flow Rate: A Randomized Controlled Subtrial Comparing Brain Injury Biomarker Release. *J Cardiothorac Vasc Anesth*. 2024 Oct;38(10):2204-2212.
  42. Alkner S, Wieslander E, Lundstedt D, Berg M, Kristensen I, Andersson Y, Bergkvist L, Frisell J, **Olofsson Bagge R**, Sund M, Christiansen P, Davide Gentilini O, Kontos M, Kühn T, Reimer T, Rydén L, Filtenborg Tvedskov T, Vrou Offersen B, Dahl Nissen H, de Boniface J; SENOMAC

- Trialists' Group. Quality assessment of radiotherapy in the prospective randomized SENOMAC trial. *Radiother Oncol*. 2024 Jun 10;197:110372.
43. Chin K, Landén AH, Kovács A, Wärnberg F, Ekholm M, Karlsson P, **Olofsson Bagge R**. Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study. *Breast Cancer Res Treat*. 2024 May 4.
  44. de Boniface J, Filtenborg Tvedskov T, Rydén L, Szulkin R, Reimer T, Kühn T, Kontos M, Gentilini OD, **Olofsson Bagge R**, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists' Group; SENOMAC Trialists' Group. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. *N Engl J Med*. 2024 Apr 4;390(13):1163-1175.
  45. **Olofsson Bagge R**, Nelson A, Shafazand A, Cahlin C, Carneiro A, Helgadottir H, Levin M, Rizell M, Ullenhag G, Wirén S, Lindnér P, Nilsson JA, Ny L. A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial). *ESMO Open*. 2024 Jul;9(7):103623.
  46. Egeler MD, van Leeuwen M, Lai-Kwon J, Eriksson H, Bartula I, Elashwah S, Fox L, Van Hemelrijck M, Jefford M, Lijnsvelt J, Bagge AL, Morag O, Ny L, **Olofsson Bagge R**, Rogiers A, Saw RPM, Serpentine S, Iannopollo L, Thompson J, Stiller HT, Vanlaer N, van Akkooi ACJ, van de Poll-Franse LV; EORTC Quality of Life Group. Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module. *Eur J Cancer*. 2024 Aug;207:114176.
  47. Neittaanmäki N, Zaar O, Cehajic KS, Nilsson KD, Katsarelias D, **Olofsson Bagge R**, Paoli J, Fletcher JS. ToF-SIMS imaging reveals changes in tumor cell lipids during metastatic progression of melanoma. *Pigment Cell Melanoma Res*. 2024 Jun 29.
  48. Hayes AJ, Coker DJ, Been L, Boecxstaens VW, Bonvalot S, De Cian F, de la Cruz-Merino L, Duarte C, Eggermont A, Farricha V, Fiore M, Grünhagen D, Grützmann R, Honoré C, Jakob J, Hocevar M, van Houdt W, Klauzner J, Kettelhack C, Märten A, Martinez-Said H, Matter M, Michot A, Niethard M, Pennacchioli E, Podleska LE, Rabago G, Rastrelli M, Reijers S, Ribeiro M, Schwarzbach M, Snow HA, Spacek M, Stoldt S, Testori A, Zoras O, **Olofsson Bagge R**. Technical considerations for isolated limb perfusion: A consensus paper. *Eur J Surg Oncol*. 2024 Mar 6;50(6):108050.
  49. Holmberg CJ, Zijlker LP, Katsarelias D, Huibers AE, Wouters MWJM, Schrage Y, Reijers SJM, van Thienen JV, Grünhagen DJ, Martner A, Nilsson JA, van Akkooi ACJ, Ny L, van Houdt WJ, **Olofsson Bagge R**. The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial). *Eur J Surg Oncol*. 2024 Jun;50(6):108265. doi: 10.1016/j.ejso.2024.108265. Epub 2024 Mar 12. PMID: 38493679.
  50. **Olofsson Bagge R**, Nelson A, Shafazand A, All-Eriksson C, Cahlin C, Elander N, Gustavsson A, Helgadottir H, Kiilgaard JF, Kinhult S, Ljuslinder I, Mattsson J, Rizell M, Sternby Eilard M, Ullenhag GJ, Nilsson JA, Ny L, Lindnér P. Survival and Quality of Life after Isolated Hepatic Perfusion with Melphalan as a Treatment for Uveal Melanoma Liver Metastases - Final Results from the Phase III Randomized Controlled Trial SCANDIUM. *Ann Surg*. 2024 Feb 29.
  51. Urzi O, Bergqvist M, Lässer C, Moschetti M, Johansson J, D Arrigo D, **Olofsson Bagge R**, Crescitelli R. Heat inactivation of foetal bovine serum performed after EV-depletion influences the proteome of cell-derived extracellular vesicles. *J Extracell Vesicles*. 2024 Jan;13(1):e12408.
  52. **Olofsson Bagge R**, Mikiver R, Marchetti MA, Lo SN, van Akkooi ACJ, Coit DG, Ingvar C, Isaksson K, Scolyer RA, Thompson JF, Varey AHR, Wong SL, Lyth J, Bartlett EK. Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status. *JAMA Surg*. 2024 Mar 1;159(3):260-268.
  53. **Olofsson Bagge R**, Berndtsson J, Urzi O, Lötvall J, Micaroni M, Crescitelli R. Three-dimensional reconstruction of interstitial extracellular vesicles in human liver as determined by electron tomography. *J Extracell Vesicles*. 2023 Dec;12(12):e12380.
  54. Corderfeldt Keiller A, Axelsson M, Bragadottir G, Blennow K, Zetterberg H, **Olofsson Bagge R**. A prospective feasibility trial exploring novel biomarkers for neurotoxicity after isolated limb perfusion. *Perfusion*. 2023 Nov 7;2676591231213506.

55. Lindqvist Bagge AS, Lekander M, **Olofsson Bagge R**, Carlander A. Mental health, stress, and well-being measured before (2019) and during (2020) COVID-19: a Swedish socioeconomic population-based study. *Psychol Health*. 2023 Sep 20:1-18.
56. Holmberg CJ, Mikiver R, Isaksson K, Ingvar C, Moncrieff M, Nielsen K, Ny L, Lyth J, **Olofsson Bagge R**. Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm). *Ann Surg Oncol*. 2023 Aug 14.
57. Wärnberg F, Wadsten C, Karakatsanis A, **Olofsson Bagge R**, Holmberg E, Lindman H, Sawyer E, Vicini F, Mann GB, Karlsson P. Outcome of different radiotherapy strategies after breast conserving surgery in patients with ductal carcinoma in situ (DCIS). *Acta Oncol*. 2023 Sep;62(9):1045-1051.
58. Reijers SJM, Davies E, Grünhagen DJ, Fiore M, Honore C, Rastrelli M, Vassos N, Podleska LE, Niethard M, Jakob J, Perhavec A, Duarte C, González F, Deroose JP, Stas M, Boecxstaens V, Schrage Y, Snow H, Algarra SM, Said HM, Garcia-Ortega DY, Martin K, Mattsson J, Djafarriar R, Di Lorenzo G, Colombo C, Gronchi A, Matter M, Verhoef C, **Olofsson Bagge R**, Hohenberger P, Hayes AJ, van Houdt WJ. Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study. *Eur J Cancer*. 2023 Sep;190:112949.
59. Lyth J, Mikiver R, Nielsen K, Ingvar C, **Olofsson Bagge R**, Isaksson K. Population-based prognostic instrument (SweMR 2.0) for melanoma-specific survival - An ideal tool for individualised treatment decisions for Swedish patients. *Eur J Surg Oncol*. 2023 Jul 3:S0748-7983(23)00567-X.
60. Janeva S, Parris TZ, Krabbe E, Sundquist M, Karlsson P, Audisio RA, **Olofsson Bagge R**, Kovács A. Clinical relevance of biomarker discordance between primary breast cancers and synchronous axillary lymph node metastases. *Clin Exp Metastasis*. 2023 Aug;40(4):299-308.
61. Helgadottir H, Ny L, Ullenhag GJ, Falkenius J, Mikiver R, **Olofsson Bagge R**, Isaksson K. Survival after Introduction of Adjuvant Treatment in Stage III Melanoma: A Nationwide Registry-Based study. *J Natl Cancer Inst*. 2023 May 25:djad081
62. Sah VR, Jespersen H, Karlsson J, Nilsson LM, Bergqvist M, Johansson I, Carneiro A, Helgadottir H, Levin M, Ullenhag G, Ståhlberg A, **Olofsson Bagge R**, Nilsson JA, Ny L. Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy. *Cancer Res Commun*. 2023 May 18;3(5):884-895.
63. Mirzaei N, Wärnberg F, Zaar P, Leonhardt H, **Olofsson Bagge R**. Ultra-Low Dose of Superparamagnetic Iron Oxide Nanoparticles for Sentinel Lymph Node Detection in Patients with Breast Cancer. *Ann Surg Oncol*. 2023 Jun 14:1-5.
64. Pucci M, Moschetti M, Urzi O, Loria M, Conigliaro A, Di Bella MA, Crescitelli R, **Olofsson Bagge R**, Gallo A, Santos MF, Puglisi C, Forte S, Lorico A, Alessandro R, Fontana S. Colorectal cancer-derived small extracellular vesicles induce TGFβ1-mediated epithelial to mesenchymal transition of hepatocytes. *Cancer Cell Int*. 2023 Apr 18;23(1):77.
65. Janeva S, Krabbe E, Parris TZ, Nasic S, Sundquist M, Karlsson P, Audisio RA, **Olofsson Bagge R**, Kovács A. Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer. *Breast Cancer Res*. 2023 Apr 6;25(1):36.
66. **Olofsson Bagge R**, Nelson A, Shafazand A, All-Eriksson C, Cahlin C, Elander N, Helgadottir H, Kiilgaard JF, Kinhult S, Ljuslinder I, Mattsson J, Rizell M, Sternby Eilard M, Ullenhag GJ, Nilsson JA, Ny L, Lindnér P. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). *J Clin Oncol*. 2023 Jun 1;41(16):3042-3050.
67. Hosein S, Drebin HM, Kurtansky NR, **Olofsson Bagge R**, Coit DG, Bartlett EK, Marchetti MA. Are the MIA and MSKCC nomograms useful in selecting patients with melanoma for sentinel lymph node biopsy? *J Surg Oncol*. 2023 Mar 11.
68. Chin K, Wärnberg F, Kovacs A, **Olofsson Bagge R**. Impact of Surgical Care Bundle on Surgical Site Infection after Non-Reconstructive Breast Cancer Surgery: A Single-Centre Retrospective Comparative Cohort Study. *Cancers (Basel)*. 2023 Feb 1;15(3):919.
69. Forsberg EMV, Riise R, Saellström S, Karlsson J, Alsén S, Bucher V, Hemminki AE, **Olofsson Bagge R**, Ny L, Nilsson LM, Rönnerberg H, Nilsson JA. Treatment with Anti-HER2 Chimeric

- Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. *Cancers (Basel)*. 2023 Jan 20;15(3):648.
70. Karakatsanis A, Eriksson S, Pistiolis L, **Olofsson Bagge R**, Nagy G, Man V, Kwong A, Wärnberg F; SentiNot Trialists Group. Delayed Sentinel Lymph Node Dissection in Patients with a Preoperative Diagnosis of Ductal Cancer In Situ by Preoperative Injection with Superparamagnetic Iron Oxide (SPIO) Nanoparticles: The SentiNot Study. *Ann Surg Oncol*. 2023 Jan 31.
  71. Holmberg CJ, Mattsson J, **Olofsson Bagge R**. Effects of the Introduction of Modern Immunotherapy on the Outcome of Isolated Limb Perfusion for Melanoma In-Transit Metastases. *Cancers (Basel)*. 2023 Jan 12;15(2):472.
  72. Wesslau H, Carlander A, Ny L, Wärnberg F, **Olofsson Bagge R**, Lindqvist Bagge AS. Tumor Burden and Health-Related Quality of Life in Patients with Melanoma In-Transit Metastases. *Cancers (Basel)*. 2022 Dec 27;15(1):161.
  73. Heiman J, Pavia J, Bock D, Haglind E, **Olofsson Bagge R**. Sick leave and predictive factors for sick leave at 12 months after breast cancer surgery in the randomized controlled physical activity trial (PhysSURG-B). *Surgeon*. 2023 Jan 2:S1479-666X(22)00136-6.
  74. Crescitelli R, Filges S, Karimi N, Urzi O, Alonso-Agudo T, Ståhlberg A, Lötvall J, Lässer C, **Olofsson Bagge R**. Extracellular vesicle DNA from human melanoma tissues contains cancer-specific mutations. *Front Cell Dev Biol*. 2022 Dec 1;10:1028854.
  75. van Dam P, Tomatis M, Ponti A, Marotti L, Aristei C, Biganzoli L, Cardoso MJ, Cheung KL, Curigliano G, De Vries J, Santini D, Sardanelli F, Rubio IT; **Eusoma Working Group**. The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres. *Eur J Cancer*. 2022 Dec;177:72-79. doi: 10.1016/j.ejca.2022.09.027.
  76. Pistiolis L, Khaki D, Kovács A, **Olofsson Bagge R**. The Effect of Melatonin Intake on Survival of Patients with Breast Cancer-A Population-Based Registry Study. *Cancers (Basel)*. 2022 Nov 29;14(23):5884.
  77. Urzi O, **Olofsson Bagge R**, Crescitelli R. The dark side of foetal bovine serum in extracellular vesicle studies. *J Extracell Vesicles*. 2022 Oct;11(10):e12271. doi: 10.1002/jev2.12271.
  78. Ahlstedt Karlsson S, Hensch I, **Olofsson Bagge R**, Wallengren C. Person-centred support programme (RESPECT intervention) for women with breast cancer treated with endocrine therapy: a feasibility study. *BMJ Open*. 2022 Oct 5;12(10):e060946.
  79. Heiman J, Onerup A, Bock D, Haglind E, **Olofsson Bagge R**. The effect of nonsupervised physical activity before and after breast cancer surgery on quality of life: Results from a randomized controlled trial (PhysSURG-B). *Scand J Surg*. 2022 Sep 15
  80. Eroglu Z, Broman KK, Thompson JF, Nijhuis A, Hieken TJ, Kottschade L, Farma JM, Hotz M, Deneve J, Fleming M, Bartlett EK, Sharma A, Dossett L, Hughes T, Gyorki DE, Downs J, Karakousis G, Song Y, Lee A, Berman RS, van Akkooi A, Stahlie E, Han D, Vetto J, Beasley G, Farrow NE, Hui JYC, Moncrieff M, Nobes J, Baecher K, Perez M, Lowe M, Ollila DW, Collichio FA, **Olofsson Bagge R**, Mattsson J, Kroon HM, Chai H, Teras J, Sun J, Carr MJ, Tandon A, Babacan NA, Kim Y, Naqvi M, Zager J, Khushalani NI. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection. *J Immunother Cancer*. 2022 Aug;10(8):e004417
  81. Moncrieff MD, Lo SN, Scolyer RA, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Nessim C, Wade R, Peach AH, Kisyova R, Mason J, Wilson ED, Nolan G, Pritchard Jones R, Johansson I, **Olofsson Bagge R**, Wright LJ, Patel NG, Sondak VK, Thompson JF, Zager JS. Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease. *J Clin Oncol*. 2022 Jul 18;JCO2102488
  82. Mulder EEAP, Johansson I, Grünhagen DJ, Tempel D, Rentroia-Pacheco B, Dwarkasing JT, Verver D, Mooyaart AL, van der Veldt AAM, Wakkee M, Nijsten TEC, Verhoef C, Mattsson J, Ny L, Hollestein LM, **Olofsson Bagge R**. Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse. *Cancers (Basel)*. 2022 Jun 9;14(12):2854.
  83. Backlund E, Yang M, Grozman V, Masucci G, Falkenius J, Eriksson H, Jovanovic B, Hammarlund K, Isacson U, Radu C, Abel E, Karlsson K, Palanco Zamora R, Wersäll P, Edbäck U, Wickström S, Darai Ramqvist E, Egyhazi Brage S, Kiessling R, Viktorsson K, Franzén B,

- Lewensohn R, **Olofsson Bagge R**, Ullenhag GJ, Ny L, Lindberg K, Helgadottir H. Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. *Acta Oncol.* 2022 May 31:1-5.
84. Corderfeldt Keiller A, Holmén A, Hansson C, Ricksten SE, Bragadottir G, **Olofsson Bagge R**. Non-invasive and invasive measurement of skeletal muscular oxygenation during isolated limb perfusion. *Perfusion.* 2022 May 16
  85. Holmberg CJ, Ny L, Hieken TJ, Block MS, Carr M, Sondak V, Örtenwall C, Katsarelias D, Dimitriou F, Menzies AM, Saw RPM, Rogiers A, Straker RJ, Karakousis G, Applewaithe R, Pallan L, Han D, Vetto JT, Gyorki D, Nan Tie E, Vitale MG, Ascierto PA, Dummer R, Cohen J, Hui JYC, Schachter J, Asher N, Helgadottir H, Chai H, Kroon H, Coventry B, Rothermel LD, Sun J, Carlino MS, Duncan Z, Broman K, Weber J, Lee A, Berman RS, Teras J, Ollila DW, Long GW, Zager JS, van Akkooi ACJ, **Olofsson Bagge R**. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study. *European Journal of Cancer.* 2022 May 25.
  86. van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, **Olofsson Bagge R**, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI; International Neoadjuvant Melanoma Consortium (INMC). Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). *Ann Surg Oncol.* 2022 Jan 28.
  87. Ahlstedt Karlsson S, Henoeh I, **Olofsson Bagge R**, Wallengren C. An intervention mapping-based support program that empowers patients with endocrine therapy management. *Eval Program Plann.* 2022 Mar 15;92:102071.
  88. Carlander A, Lekander M, Asmundson GJG, Taylor S, **Olofsson Bagge R**, Lindqvist Bagge AS. COVID-19 related distress in the Swedish population: Validation of the Swedish version of the COVID Stress Scales (CSS). *PLoS One.* 2022 Feb 14;17(2):e0263888.
  89. Broman KK, Hughes TM, Bredbeck BC, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, O'shea K, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Hotz M, Farma JM, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, **Olofsson Bagge R**, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley GM, Hui JYC, Been L, Kruijff S, Sinco B, Sarnaik AA, Sondak VK, Zager JS, Dossett LA; International High Risk Melanoma Consortium. International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node Positive Melanoma at Major Referral Centers. *Ann Surg.* 2022 Jan 27.
  90. Ekström K, Crescitelli R, Pétursson HI, Johansson J, Lässer C, **Olofsson Bagge R**. Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer. *BMC Cancer.* 2022 Jan 10;22(1):50.
  91. Mirzaei N, Katsarelias D, Zaar P, Jalnefjord O, Johansson I, Leonhardt H, Wärnberg F, **Olofsson Bagge R**. Sentinel lymph node localization and staging with a low-dose of superparamagnetic iron oxide (SPIO) enhanced MRI and magnetometer in patients with cutaneous melanoma of the extremity - The MAGMEN feasibility study. *Eur J Surg Oncol.* 2022 Jan 1:S0748-7983(21)01439-6.
  92. Johansson I, Levin M, Akyürek LM, **Olofsson Bagge R**, Ny L. PD-1 inhibitor therapy of basal cell carcinoma with pulmonary metastasis. *JEADV.* 2022 Jan (36) Issue S1:70-73
  93. Johansson I, Tempel D, Dwarkasing JT, Rentroia-Pacheco B, Mattsson J, Ny L, **Olofsson Bagge R**. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. *Eur J Surg Oncol.* 2021 Nov 10:S0748-7983(21)00814-3.
  94. Lindqvist Bagge AS, Wesslau H, Cizek R, Holmberg CJ, Moncrieff M, Katsarelias D, Carlander A, **Olofsson Bagge R**. Health-related quality of life using the FACT-M questionnaire in patients with malignant melanoma: A systematic review. *Eur J Surg Oncol.* 2021 Sep 20:S0748-7983(21)00739-3.

95. Bethlehem MS, Katsarelias D, **Olofsson Bagge R**. Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases. *Cancers (Basel)*. 2021 Sep 21;13(18):4726.
96. Ny L, Jespersen H, Karlsson J, Alsén S, Filges S, All-Eriksson C, Andersson B, Carneiro A, Helgadottir H, Levin M, Ljuslinder I, **Olofsson Bagge R**, Sah VR, Stierner U, Ståhlberg A, Ullenhag G, Nilsson LM, Nilsson JA. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. *Nat Commun*. 2021 Aug 27;12(1):5155.
97. Heiman J, Onerup A, Wessman C, Haglind E, **Olofsson Bagge R**. Recovery after breast cancer surgery following recommended pre and postoperative physical activity: (PhysSURG-B) randomized clinical trial. *Br J Surg*. 2021 Jan 27;108(1):32-39.
98. Eriksson H, Utjés D, **Olofsson Bagge R**, Gillgren P, Isaksson K, Lapins J, Schultz IL, Lyth J, Andersson TM. The Proportion Cured of Patients with Resected Stage II-III Cutaneous Melanoma in Sweden. *Cancers (Basel)*. 2021 May 18;13(10):2456.
99. Roberta Kiffin, Junko Johansson, **Roger Olofsson Bagge**, Anna Martner. Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma. *European Journal of Surgical Oncology*, 2021 May 5.
100. Janeva S, Parris TZ, Nasic S, De Lara S, Larsson K, Audisio RA, **Olofsson Bagge R**, Kovács A. Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens. *BMC Cancer*. 2021 Apr 21;21(1):439.
101. Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, **Olofsson Bagge R**, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy trial II (MSLT-2). *Cancer*. 2021 Apr 7.
102. Broman KK, Hughes TM, Dossett LA, Sun J, Carr MJ, Kirichenko DA, Sharma A, Bartlett EK, Nijhuis AA, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma J, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, **Olofsson Bagge R**, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras RM, Teras J, Farrow NE, Beasley GM, Hui JY, Been L, Kruijff S, Boulware D, Sarnaik AA, Sondak VK, Zager JS; International High-Risk Melanoma Consortium. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. *J Am Coll Surg*. 2021 Apr;232(4):424-431.
103. **Olofsson Bagge R**, Ny L, Ascierto PA, Hodi FS, Larkin J, Robert C, Schachter J, Weber JS, Long GV, van Akkooi ACJ. The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. *Melanoma Res*. 2021 Feb 18.
104. Hersi A-F, Pistiolis L, Dussan Lubert C, Vikhe-Patil E, Nilsson F, Mohammed I, **Olofsson Bagge R**, Wärnberg F, Eriksson S, Karakatsanis A. Optimizing Dose and Timing in Magnetic Tracer Techniques for Sentinel Lymph Node Detection in Early Breast Cancers: The Prospective Multicenter SentiDose Trial. *Cancers*. 2021; 13(4):693
105. Broman KK, Hughes TM, Dossett LA, Sun J, Carr M, Kirichenko DA, Sharma A, Bartlett EK, Nijhuis AA, Thompson JF, Hieken TJ, Downs J, Gyorki D, Stahlie E, van Akkooi A, Ollila DW, Frank Jill, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma J, Deneve J, Fleming MD, Perez M, Baecher K, Lowe M, **Olofsson Bagge R**, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras RM, Teras J, Farrow NE, Beasley GM, Hui JY, Been L, Kruijff S, Boulware D, Sarnaik AA, Sondak VK, Zager JS. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. *J Am Coll Surg*. 2020 Dec 13:S1072-7515(20)32521-7.
106. Johansson J, Siarov J, Kiffin R, Mölne J, Mattsson J, Naredi P, **Olofsson Bagge R**, Martner A, Lindnér P. Presence of tumor-infiltrating CD8<sup>+</sup> T cells and macrophages correlates to longer

- overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis. *Oncoimmunology*. 2020 Dec 10;9(1):1854519
107. Janeva S, Zhang C, Kovacs A, Parris T, Crozier JA, Pezzi CM, Linderholm B, Audisio RA, **Olofsson Bagge R**. Adjuvant chemotherapy and survival in women aged 70 years and older with triple-negative breast cancer: a Swedish population-based propensity score-matched analysis. *The Lancet Healthy Longevity*. 2020 Dec 1;1(3) E117-E124
  108. Katsarelias D, Eriksson H, Mikiver R, Krakowski I, Nilsson JA, Ny L, **Olofsson Bagge R**. The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma-A Nation-Wide Swedish Population-Based Retrospective Register Study. *Cancers*. 2020 Nov 2;12(11)
  109. Holmberg CJ, Katsarelias D, Jespersen H, Carneiro A, Elander NO, Helgadottir H, Isaksson K, Jansson M, Wirén S, Ullenhag GJ, Ny L, **Olofsson Bagge R**. Surgery of metastatic melanoma after systemic therapy - the SUMMIST trial: study protocol for a randomized controlled trial. *Acta Oncol*. 2020 Nov 30:1-4.
  110. Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, **Olofsson Bagge R**, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Michielin O. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. *Ann Oncol*. 2020 Aug 4:S0923-7534(20)39939-7
  111. Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, **Olofsson Bagge R**, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Keilholz U. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. *Ann Oncol*. 2020 Aug 4:S0923-7534(20)39940-3
  112. **Olofsson Bagge R**, Kicinski M, Faries MB, Gyorki DE, Isaksson K, Katsarelias D, Lo S, Moncrieff M, Spillane A, Suci S, van Akkooi A. Comment on Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. *J Clin Oncol*. 2020 Jul 23
  113. Lindqvist Bagge AS, Carlander A, Fahlke C, **Olofsson Bagge R**. Health-related quality of life (FACT-GP) in Sweden. *Health Qual Life Outcomes*. 2020;18(1):172.
  114. Wallerstedt SM, Nilsson Ek A, **Olofsson Bagge R**, Kovács A, Strandell A, Linderholm B. Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence - a systematic review and meta-analysis. *Eur J Clin Pharmacol*. 2020;10.1007
  115. Kantere D, Siarov J, De Lara S, Parhizkar S, **Olofsson Bagge R**, Wennberg Larkö AM, Ericson MB. Label-free laser scanning microscopy targeting sentinel lymph node diagnostics: A feasibility study ex vivo. *Translational Biophotonics*. 2020 Aug 3(2):e202000002
  116. Karlsson J, Nilsson LM, Mitra S, Alsén S, Shelke GV, Sah VR, Forsberg EMV, Stierner U, All-Eriksson C, Einarsdottir B, Jespersen H, Ny L, Lindnér P, Larsson E, **Olofsson Bagge R**, Nilsson JA. Molecular profiling of driver events in metastatic uveal melanoma. *Nature Commun*. 2020 Apr 20;11(1):1894.
  117. Moncrieff MD, O'Leary FM, Beadsmoore CJ, Pawaroo D, Heaton MJ, Isaksson K, **Olofsson Bagge R**. Effect of delay between nuclear medicine scanning and sentinel node biopsy on outcome in patients with cutaneous melanoma. *Br J Surg*. 2020 Feb
  118. de Boniface J, Ahlgren J, Andersson Y, Bergkvist L, Frisell J, Lundstedt D, **Olofsson Bagge R**, Rydén L, Sund M. The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer. *Breast Cancer Res Treat*. 2020 Epub.
  119. Ahlstedt Karlsson S, Wallengren C, **Olofsson Bagge R**, Hensch I. Women's coping strategies during the first three months of adjuvant endocrine therapy for breast cancer. *Nurs Open*. 2019 Dec 13;7(2):605-612
  120. Johansson J, Kiffin R, Aydin E, Nilsson MS, Hellstrand K, Lindnér P, Naredi P, **Olofsson Bagge R**, Martner A. Isolated limb perfusion with melphalan activates interferon-stimulated

- genes to induce tumor regression in patients with melanoma in-transit metastasis. *Oncoimmunology*. 2019 Nov 3;9(1)
121. Ny L, Rizzo Y, Belgrano V, Karlsson J, Jespersen H, Carstam L, **Olofsson Bagge R**, Nilsson L.M, Nilsson J.A. Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. *Ann Onc*. 2019 Epub.
  122. Ekenberg M, Wesslau H, **Olofsson Bagge R**, Engström M. Patient experiences with isolated limb perfusion for malignant melanoma – A qualitative study. *Eur J Oncol Nurs*. 2019 Oct 4;43:101672
  123. Corderfeldt A, Nielsen S, Katsarelias D, Hjärpe A, Mattsson J, **Olofsson Bagge R**. Is blood a necessary component of the perfusate during isolated limb perfusion – a randomized controlled trial. *Int J Hyperthermia*. 2019; 36(1).
  124. Jang SC, Crescitelli R, Cvjetkovic A, Belgrano V, **Olofsson Bagge R**, Sundfeldt K, Ochiya T, Kalluri R, Lötvall J. Mitochondrial protein enriched extracellular vesicles discovered in human melanoma tissues can be detected in patient plasma. *Journal of Extracellular Vesicles*. 2019; 8 (1).
  125. Jespersen H, **Olofsson Bagge R**, Ullenhag G, Carneiro A, Helgadóttir H, Ljuslinder I, Levin M, All-Eriksson C, Andersson B, Stierner U, Nilsson LM, Nilsson JA, Ny L. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. *BMC Cancer*. 2019 May 2;19(1):415
  126. Holmberg CJ, Alwan G, Ny L, **Olofsson Bagge R**, Katsarelias D. Surgery for gastrointestinal metastases of malignant melanoma - a retrospective exploratory study. *World J Surg Oncol*. 2019 Jul 12;17(1):123.
  127. Sandblom V, Ståhl I, Hansson C, **Olofsson Bagge R**, Forssell-Aronsson E. Local treatment of liver metastases by administration of 177Lu-octreotate via isolated hepatic perfusion - A preclinical simulation of a novel treatment strategy. *Surg Oncol*. 2019 Jun;29:148-156.
  128. Isaksson K, Katsarelias D, Mikiver R, Carneiro A, Ny L, **Olofsson Bagge R**. A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. *Ann Surg Oncol*. 2019 May 20.
  129. Belgrano V, Mattsson J, Nilsson J, **Olofsson Bagge R**, Katsarelias D. BRAF status as a predictive factor for response in isolated limb perfusion. *Int J Hyperthermia*. 2019;36(1):511-515.
  130. Katsarelias D, Båth J, Carlson P, Mattsson J, **Olofsson Bagge R**. Leakage through the bone-marrow during isolated limb perfusion in the lower extremity. *Journal of Surgical Case Reports* Volume 2019, Issue 4, April 2019
  131. Karakatsanis A, Hersi AF, Pistiolis L, **Olofsson Bagge R**, Lykoudis PM, Eriksson S, Wärnberg F. Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ. *Br J Surg*. 2019 Mar 6.
  132. Forsberg EM, Lindberg MF, Jespersen H, Alsén S, **Olofsson Bagge R**, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA. HER2 CAR-T cells eradicate uveal melanoma and T cell therapy-resistant human melanoma in interleukin-2 (IL-2) transgenic NOD/SCID IL-2 receptor knockout mice. *Cancer Res*. 2019 Jan 8.
  133. Ahlstedt Karlsson S, Wallengren C, **Olofsson Bagge R**, Hensch I. "It is not just any pill"- Women's experiences of endocrine therapy after breast cancer surgery. *Eur J Cancer Care*. 2019 Feb 12
  134. Belgrano V, Pettersson J, Nilsson JA, Mattsson J, Katsarelias D, **Olofsson Bagge R**. Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma. *Ann Surg Oncol*. 2019 Jan 7.
  135. **Olofsson Bagge R**, Demir A, Karlsson J, Alaei-Mahabadi B, Einarsdóttir B, Jespersen H, Lindberg MF, Muth A, Nilsson L, Persson M, Svensson J, Söderberg E, de Krijger R, Nilsson O, Larsson E, Stenman G, and Nilsson JA. Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary. *JCO Precision Oncology* 2018 :2, 1-25

136. **Olofsson Bagge R**, Carlson P, Razzazian R, Hansson C, Hjärpe A, Mattsson J, Katsarelias D. Minimally invasive isolated limb perfusion - technical details and initial outcome of a new treatment method for limb malignancies. *Int J Hyperthermia*. 2018 Nov 14;1-7
137. Johansson J, Kiffin R, Andersson A, Lindnér P, Naredi P, **Olofsson Bagge R**, Martner A. Isolated limb perfusion with melphalan triggers immune activation in melanoma patients. *Front Oncol*. 2018 Dec 3;8:570.
138. Stenmark Tullberg A, Lundstedt D, **Olofsson Bagge R**, Karlsson P (2018) Positive sentinel node in luminal A-like breast cancer patients - implications for adjuvant chemotherapy? *Acta Oncologica*.
139. Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, **Olofsson Bagge R**, Carstam L, Scobie M, Koolmeister T, Wallner O, Stierner U, Berglund UW, Ny L, Nilsson LM, Larsson E, Helleday T, Nilsson JA. A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. *Cell Death Dis*. 2018 Jul 24;9(8):810.
140. Moncrieff MD, Gyorki D, Saw R, Spillane AJ, Peach H, Oudit D, Geh J, Dziwulski P, Wilson E, Matteucci P, Pritchard-Jones R, **Olofsson Bagge R**, Wright FC, Crampton N, Cassell O, Jallali N, Berger A, Kelly J, Hamilton S, Durrani A, Lo S, Paton E, Henderson MA. 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. *Ann Surg Oncol*. 2018 May 30.
141. Katsarelias D, Rådbo E, Ben-Shabat I, Mattsson J, **Olofsson Bagge R**. The Effect of Temperature and Perfusion Time on Response, Toxicity, and Survival in Patients with In-transit Melanoma Metastases Treated with Isolated Limb Perfusion. *Ann Surg Oncol*. 2018 May 15
142. Pétursson HI, Kovács A, Mattsson J, **Olofsson Bagge R**. Evaluation of intraoperative touch imprint cytology on axillary sentinel lymph nodes in invasive breast carcinomas, a retrospective study of 1227 patients comparing sensitivity in the different tumor subtypes. *PLoS One*. 2018 Apr 12;13(4)
143. Muralidharan SV, Einarsdottir BO, Bhadury J, Lindberg MF, Wu J, Campeau E, **Olofsson Bagge R**, Stierner U, Ny L, Nilsson LM, Nilsson JA. BET bromodomain inhibitors synergize with ATR inhibitors in melanoma in melanoma. *Cell Death Dis*. 2017 Aug 10;8(8)
144. Lunavat T, Cheng L, Einarsdottir B, **Olofsson Bagge R**, Muralidharan S, Sharples R, Lässer C, Gho YS, Hill AF, Nilsson J, Lötval J. BRAF<sup>V600</sup> inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells. *PNAS*. Epub
145. de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Rydén L, **Olofsson Bagge R**, Sund M, Johansson H, Lundstedt D. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. *BMC Cancer*. 2017 May 26;17(1):379.
146. Nyström Wendt A, Mattsson J, **Olofsson Bagge R**. Myoglobin Does Not Predict Local Toxicity in Isolated Limb Perfusion. *Int J Hyperthermia*. 2017 Sep;33(6):679-683.
147. Ben-Shabat I, Belgrano V, Hansson C, **Olofsson Bagge R**. The Effect of Perfusate Buffering on Toxicity and Response in Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases. *Int J Hyperthermia*. 2017 Jan 22;1-17
148. Sandblom V, Ståhl I, **Olofsson Bagge R**, Forssell-Aronsson E. Evaluation of two intraoperative gamma detectors for assessment of 177Lu activity concentration in vivo. *EJNMMI Phys*. 2017 Dec;4(1):3
149. Heiman Ullmark J, Sahlin C, Hallberg H, **Olofsson Bagge R**. Breast-Conserving Surgery Using an Inframammary Fold Incision Technique for Breast Cancer. *J Plast Surg Hand Surg*. 2016 Jun 22;1-7.
150. Belgrano V, Ben-Shabat I, Bergh P, **Olofsson Bagge R**. Isolated Limb Perfusion as a Treatment Option for Rare Types of Tumours. *Int J Hyperthermia*. 2016 Sep;32(6):595-9.
151. Bhadury J, Einarsdottir BO, Podraza A, **Olofsson Bagge R**, Stierner U, Ny L, Dávila López M, Nilsson JA. Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. *Oncotarget*. 2016 Mar 18. doi: 10.18632/oncotarget.8181.
152. Ben-Shabat I, Belgrano V, Ny L, Nilsson J, Lindnér P, **Olofsson Bagge R**. Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. *Ann Surg Oncol*. 2016 Apr;23(4):1327-34

153. Dossett L, Ben-Shabat I, **Olofsson Bagge R**, Zager J. Clinical response and regional toxicity following isolated limb infusion compared to isolated limb perfusion for in-transit melanoma. *Ann Surg Oncol*. 2016 Feb 11.
154. Lindqvist Bagge AS, Ben-Shabat I, Belgrano I, **Olofsson Bagge R**. Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion. *Ann Surg Oncol*. 2016 Feb 11.
155. Martner A, Johansson J, Ben-Shabat I, **Olofsson Bagge R**. Melphalan, anti-melanoma immunity and inflammation. *Cancer Research*. 2015 Dec 15;75(24):5398-9
156. Belgrano V, **Olofsson Bagge R**, Scordamaglia C, Scordamaglia R. Extraction of a foreign body in the liver using single incision laparoscopic surgery: a new application for minimally invasive surgical procedures. *Videosurgery and other minimal invasive techniques*. 2015 Apr;10(1):129-32
157. Ben-Shabat I, Hansson C, Sternby Eilard M, Cahlin C, Rizell M, Lindnér P, Mattsson J, **Olofsson Bagge R**. Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma. *J Vis Exp*. 2015 Jan 25;(95):52490
158. Eldh M, **Olofsson Bagge R**, Lässer C, Svanvik J, Sjöstrand M, Mattsson J, Lindner P, Choi DS, Gho YS and Lotvall J. MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma. *BMC Cancer*. 2014 Dec 16;14(1):962
159. Einarsdottir B, **Olofsson Bagge R**, Bhadury J, Jespersen H, Mattsson J, Nilsson L, Truvé K, Dávila López M, Naredi P, Nilsson O, Stierner U, Ny L, Nilsson J. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. *Oncotarget*. 2014 Oct 30;5(20):9609-18
160. **Olofsson R**, Mattsson M, Hafström Lo. Regional Hyperthermic Perfusion With Melphalan After Surgery for Recurrent Malignant Melanoma of the Extremities – Long Term Follow-Up of A Randomized Trial. *Int J Hyperthermia*. 2014 Sep;30(5):295-298
161. **Olofsson R**, Ny L, Sternby Eilard M, Rizell M, Cahlin C, Stierner U, Lönn U, Hansson J, Ljuslinder I, Lundgren L, Ullenhag G, Kiilgaard JF, Nilsson J, Lindnér P. Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. *Trials*. 2014 Aug 9;15(1):317.
162. Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Ström CE, Svensson LM, Schultz N, Lundbäck T, Einarsdottir BO, Saleh A, Göktürk C, Baranczewski P, Svensson R, Berntsson RP, Gustafsson R, Strömberg K, Sanjiv K, Jacques-Cordonnier MC, Desroses M, Gustavsson AL, **Olofsson Bagge R**, Johansson F, Homan EJ, Loseva O, Bräutigam L, Johansson L, Höglund A, Hagenkort A, Pham T, Altun M, Gaugaz FZ, Vikingsson S, Evers B, Henriksson M, Vallin KS, Wallner OA, Hammarström LG, Wiita E, Almlöf I, Kalderén C, Axelsson H, Djureinovic T, Puigvert JC, Häggblad M, Jeppsson F, Martens U, Lundin C, Lundgren B, Granelli I, Jensen AJ, Artursson P, Nilsson JA, Stenmark P, Scobie M, Berglund UW, Helleday T. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. *Nature*. 2014 Apr 10;508(7495):215-21.
163. **Olofsson R**, Cahlin C, All-Ericsson C, Hashimi F, Mattsson J, Rizell M, Lindnér P. Isolated Hepatic Perfusion for Ocular Melanoma Metastasis - Registry Data Suggests a Survival Benefit. *Ann Surg Oncol*. 2014 Feb;21(2):466-72
164. **Olofsson R**, Mattsson J, Lindnér P. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma. *Int J Hyperthermia*. 2013 Sep;29(6):551-7
165. **Olofsson R**, Lindberg E, Karlsson-Parra A, Lindnér P, Mattsson J, Andersson B. Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma. *Int J Hyperthermia*. 2013 May;29(3):234-8.
166. **Olofsson R**, Bergh P, Berlin O, Engström K, Gunterberg B, Hansson M, Lindnér P, Mattsson J. Long-Term Outcome of Isolated Limb Perfusion in Advanced Soft Tissue Sarcoma of the Extremity. *Ann Surg Oncol*. 2012 Jun;19(6):1800-7.
167. **Olofsson R**, Oltean M, Olausson M. Intestinal preservation injury: a comparison between different rat strains. 2006 *Trans Proc* Jul-Aug;38(6):1789-91.

168. Oltean M, **Olofsson R**, Zhu C, Mera S, Blomgren K, Olausson M. FK506 donor pretreatment improves intestinal graft microcirculation and morphology by concurrent inhibition of early NF-kappaB activation and augmented HSP72 synthesis. 2005 *Trans Proc May*; 37(4):1931-3.
169. Oltean M, Mera S, **Olofsson R**, Zhu C, Blomgren K, Hallberg E, Olausson M. Transplantation of preconditioned intestinal grafts is associated with lower systemic inflammatory activation and remote organ injury in rats. 2006 *Trans Proc Jul-Aug*;38(6):1775-8.

#### REVIEW ARTICLES

170. Huibers A, Wong A, Burgmans M, Ny L, Stålhammar G, Kapiteijn E, Zager JS, **Olofsson Bagge R**. Management of liver metastases from uveal melanoma. *Br J Surg*. 2025 Aug 1;112(8):znaf130. doi: 10.1093/bjs/znaf130. PMID: 40794619.
171. Urzi O, **Olofsson Bagge R**, Crescitelli R. Extracellular vesicles in uveal melanoma - biological roles and diagnostic value. *Cancer Lett*. 2025 Feb 4:217531.
172. Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, **Olofsson Bagge R**, Harbour JW, Chieng ND, Patel SP, Joshua AM, Piperno-Neumann S. Advances in the clinical management of uveal melanoma. *Nat Rev Clin Oncol*. 2023 Feb;20(2):99-115.
173. **Olofsson Bagge R**, Hieken TJ. A new era of risk prediction for patients with high-risk melanoma. *Lancet Oncol*. 2024 Apr;25(4):415-416.
174. Huibers A, DePalo DK, Perez MC, Zager JS, **Olofsson Bagge R**. Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver. *Clin Exp Metastasis*. 2023 Oct 16.
175. DePalo DK, Perez MC, Huibers A, **Olofsson Bagge R**, Zager JS. Oncolytic intralesional therapy for metastatic melanoma. *Clin Exp Metastasis*. 2023 Aug 9.
176. Pistoli L, Katsarelias D, Audisio RA, **Olofsson Bagge R**. The Intricate Relationship between Melatonin and Breast Cancer: A Short Review. *Chirurgia*. 2021 Mar-Apr;116(2 Suppl):24-34.
177. Hansson E, Brorson F, Chin, K, Hallberg H, Heiman Ullmark J, Jivegård L, Magnusson K, **Olofsson Bagge R**, Svanberg T, Strandell A. Impact of postmastectomy radiotherapy on complications and results of immediate breast reconstruction. Göteborg: Västra Götalandsregionen, Sahlgrenska Universitetssjukhuset, HTA-centrum: 2019. Regional activity-based HTA 2019:106
178. Nilsson Ek A, Kovacs A, Linderholm B, **Olofsson Bagge R**, Stadig I, Svanberg T, Wallerstedt SM, Strandell A. Gene expression profiles to guide adjuvant chemotherapy in luminal, HER2-negative breast cancer. Västra Götalandsregionen, Sahlgrenska Universitetssjukhuset, HTA-centrum: 2019. Regional activity-based HTA 2019:107
179. Nilsson JA, **Olofsson Bagge R**, Ny L. Mouse avatars take off as cancer models. *Nature*. 2018 Oct;562(7726):192.
180. **Olofsson Bagge R**, Ny L. Adjuvant therapies for malignant melanoma. *Br J Surg*. 2016 Aug;103(9):1095-6.
181. Naredi P, **Olofsson Bagge R**. Present and future role of surgery in metastatic gastrointestinal malignancies. *Curr Opin Oncol*. 2016 Jul;28(4):348-52.

#### OTHER ARTICLES

182. Grunhagen DJ, Bartlett EK, **Olofsson Bagge R**, Suci S, van Akkooi ACJ; International Melanoma Consortium group. On the survival benefit from sentinel node biopsy for melanoma. *Lancet Oncol*. 2026 Jun;27(6):e274.
183. Dugan MM, **Olofsson Bagge R**, Zager JS. ASO Author Reflections: Management of Melanoma In-Transit Metastasis with Isolated Limb Infusion or Perfusion as First-Line versus Second-Line Therapy. *Ann Surg Oncol*. 2025 May 7.
184. Riaz N, **Olofsson Bagge R**. ASO Author Reflections: Nevus-Associated Melanoma: A Prognostically Distinct Entity. *Ann Surg Oncol*. 2025 Feb 18.
185. Katsarelias D, Isaksson K, **Olofsson Bagge R**. ASO Author Reflections: Effects of the Updated AJCC Classification for Patients with Stage III Melanoma. *Ann Surg Oncol*. 2019 Aug 29.
186. Katsarelias D, **Olofsson Bagge R**. ASO Author Reflections: The Future of Isolated Limb Perfusion. *Ann Surg Oncol*. 2018 Nov 8.

---

## ABSTRACTS PRESENTED AT CONFERENCES FROM 2020 AND ONWARDS

---

1. de Boniface J, Tvedskov TF, Rydén L, Szulkin R, Appelgren M, Reimer T, Kühn T, Kontos M, Gentilini OD, **Olofsson Bagge R**, Sund M, Lundstedt D, Ahlgren J, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists' Group. Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial (LBA503), 2026 ASCO Annual Meeting, May 29–June 2, 2026, Chicago, IL, USA. *J Clin Oncol.*2026;44(Suppl 17):LBA503.
2. Balsay-Patel C, Dugan M, Hussnain Naqvi SM, Ollila DW, Hieken TJ, van Houdt WJ, Asher N, Broman KK, Snow H, Farma JM, Vetto JT, Hui JYC, Saw RP, Lo SN, Long GV, Ny L, Kim Y, van Akkooi AC, **Olofsson Bagge R**, Zager JS. A propensity score-matched analysis comparing first-line regional, systemic, and intralesional treatments for melanoma in-transit metastases in a contemporary patient population (9524), 2026 ASCO Annual Meeting, May 29–June 2, 2026, Chicago, IL, USA. *J Clin Oncol.* 2026;44(Suppl 16):9524.
3. Nelson A, Krabbe E, Björkström K, Huibers A, Blank CU, Jovanovic B, Kadefors M, Carneiro A, Isaksson K, Wirén S, Wallander M, Valachis A, Ullenhag GJ, Helgadottir H, Ny L, **Olofsson Bagge R**. Outcome of neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: A Swedish nationwide population-based study (NEO-MEL) (9565), 2026 ASCO Annual Meeting, May 29–June 2, 2026, Chicago, IL, USA. *J Clin Oncol.* 2026;44(Suppl 16):9565.
4. Nelson A, Krabbe E, Björkström K, Huibers A, Blank CU, Jovanovic B, Kadefors M, Carneiro A, Isaksson K, Wirén S, Wallander M, Valachis A, Ullenhag GJ, Helgadottir H, Ny L, **Olofsson Bagge R**. Adjuvant versus no adjuvant therapy after major pathological response to neoadjuvant immunotherapy in resectable melanoma: A Swedish nationwide population-based study (NEO-MEL) (9566), 2026 ASCO Annual Meeting, May 29–June 2, 2026, Chicago, IL, USA. *J Clin Oncol.* 2026;44(Suppl 16):9566.
5. Farooq MS, Balsay-Patel C, Leong SP, Olofsson Bagge R, Kashani-Sabet M, White RL Jr, Vetto JT, Schneebaum S, Howard JH, Avisar E, Namm JP, Kosiorek HE, Pockaj BA, Orcutt ST, Crystal JS, Faries MB, Hieken TJ, Zager JS, Karakousis GC, O'Donoghue C. Assessment of recurrence risk in stage IIB/C melanoma across time: Implications for stratification and surveillance (9568), 2026 ASCO Annual Meeting, May 29–June 2, 2026, Chicago, IL, USA. *J Clin Oncol.* 2026;44(Suppl 16):9568.
6. Helgadottir H, Olofsson Bagge R. Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study (A-124), 22nd EADO Congress, April 23-25 2026, Prague, Czech Republic.
7. Markwart M, Huibers A, Olofsson Bagge R, Azimifar B, Neittaanmäki N. Validation of ex-vivo confocal microscopy with on-site immunohistochemistry for rapid detection of lymph node melanoma metastases. 4th World Congress on Confocal Microscopy, 4-6 January 2026, Naples, Italy.
8. Mohammad Saad Farooq, Caitlyn Balsay-Patel, Stanley P. L. Leong, Roger Olofsson Bagge, Mohammed Kashani-Sabet, Richard L. White Jr., John T. Vetto, Shlomo Schneebaum, John Harrison Howard, Eli Avisar, Jukes P. Namm, Heidi E. Kosiorek, Barbara A. Pockaj, Sonia Tewani Orcutt, Jessica S. Crystal, Mark B Faries, Tina J. Hieken, Jonathan S. Zager, Giorgos Constantine Karakousis, Cristina O'Donoghue. Assessment of recurrence risk in stage IIB/C melanoma across time: implications for stratification and surveillance. ASCO Annual Meeting 20206, May 29 - June 2, 2026, Chicago, USA.
9. Caitlyn Balsay-Patel, Michelle Dugan, Syeda Mahrukh Hussnain Naqvi, David W. Ollila, Tina J. Hieken, Winan J. van Houdt, Nethanel Asher, Kristy Kummerow Broman, Hayden Snow, Jeffrey M. Farma, John T. Vetto, Jane Yuet Ching Hui, Robyn P.M. Saw, Serigne N Lo, Georgina V. Long, Lars Ny, Youngchul Kim, Alexander Christopher Jonathan van Akkooi, Roger Olofsson Bagge, Jonathan S. Zager. A propensity score-matched analysis comparing first-line regional, systemic, and intralesional treatments for melanoma in-transit

- metastases in a contemporary patient population. ASCO Annual Meeting 20206, May 29 - June 2, 2026, Chicago, USA.
10. Axel Nelson, Ellen Krabbe, Karl Björksrtöm, Anne Huibers, Christian U. Blank, Braslav Jovanovic, Måns Kadefors, Ana Carneiro, Karolin Isaksson, Sara Wirén, Mikael Wallander, Antonios Valachis, Gustav Jörgen Ullenhag, Hildur Helgadóttir, Lars Ny, Roger Olofsson Bagge. Adjuvant versus no adjuvant therapy after major pathological response to neoadjuvant immunotherapy in resectable melanoma: a Swedish nationwide population-based study (NEO-MEL). ASCO Annual Meeting 20206, May 29 - June 2, 2026, Chicago, USA.
  11. Axel Nelson, Ellen Krabbe, Karl Björksrtöm, Anne Huibers, Christian U. Blank, Braslav Jovanovic, Måns Kadefors, Ana Carneiro, Karolin Isaksson, Sara Wirén, Mikael Wallander, Antonios Valachis, Gustav Jörgen Ullenhag, Hildur Helgadóttir, Lars Ny, Roger Olofsson Bagge. Outcome of neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: a Swedish nationwide population-based study (NEO-MEL). ASCO Annual Meeting 20206, May 29 - June 2, 2026, Chicago, USA.
  12. Jana de Boniface, Tove Filtenborg Tvedskov, Lisa Rydén, Robert Szulkin, Matilda Appelgren, Toralf Reimer, Thorsten Kühn, Michalis Kontos, Oreste Davide Gentilini, Roger Olofsson Bagge, Malin Sund, Dan Lundstedt, Johan Ahlgren, Sara Alkner, Yvette Andersson, Birgitte Vrou Offeresen, Leif Bergkvist, Jan Frisell, Peer Christiansen, SENOMAC Trialists' Group. Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial. ASCO Annual Meeting 20206, May 29 - June 2, 2026, Chicago, USA.
  13. Elodie Barthout, Georgios Panagiotis Sigalas, Amin Ravaei, Björg Kristjansdóttir, Cecilia Lässer, Emma Symonds, Roger Olofsson Bagge, Karin Sundfeldt, Jan Lötvall, Rossella Crescitelli. Mitochondrial protein signatures of tumor-derived extracellular vesicles reveal potential biomarkers for ovarian cancer. International Society of Extracellular Vesicles (ISEV), 23-26 Apr 2026, Puerto Rico
  14. M. Ernestson, Fredrik Wärnberg, Nushin Mirzaei et al. Early experience of vacuum assisted excision for breast lesions – the VAEBreast study. 44th Congress of the European Society of Surgical Oncology (ESSO), 15–17 Oct 2025, Gothenburg, Sweden.
  15. Anne E. Huibers, Anna Constantinescu, Roger Olofsson Bagge. Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis. 44th Congress of the European Society of Surgical Oncology (ESSO), 15–17 Oct 2025, Gothenburg, Sweden.
  16. P. Teterycz, E. Symonds, Roger Olofsson Bagge. Validation of a new high risk group in stage pT1bN0 cutaneous melanoma. 44th Congress of the European Society of Surgical Oncology (ESSO), 15–17 Oct 2025, Gothenburg, Sweden.
  17. E. Krabbe, Axel Nelson, Roger Olofsson Bagge. Neoadjuvant immunotherapy for patients with resectable stage III cutaneous melanoma – a comparison between response in lymph node metastasis and in-transit metastasis. 44th Congress of the European Society of Surgical Oncology (ESSO), 15–17 Oct 2025, Gothenburg, Sweden.
  18. Nazia Riaz, Stanley P. Leong, Roger Olofsson Bagge. Prognostic value of non-nodal regional metastasis in predicting sentinel lymph node status in cutaneous melanoma. 44th Congress of the European Society of Surgical Oncology (ESSO), 15–17 Oct 2025, Gothenburg, Sweden.
  19. E. Krabbe, Nazia Riaz, Roger Olofsson Bagge. Pattern of regional recurrences in patients with trunk melanoma and implications for ultrasound follow-up. 43rd Congress of the European Society of Surgical Oncology (ESSO), 2–4 Oct 2024, Antwerp, Belgium.
  20. Anne E. Huibers, Stanley P. Leong, Roger Olofsson Bagge. Predict In Transit: identifying predictive factors for the development of in-transit metastasis in patients with melanoma. 43rd Congress of the European Society of Surgical Oncology (ESSO), 2–4 Oct 2024, Antwerp, Belgium.
  21. Nazia Riaz, Anne Huibers, Roger Olofsson Bagge. Prognostic value of pre-existing nevi in patients with melanoma. 43rd Congress of the European Society of Surgical Oncology (ESSO), 2–4 Oct 2024, Antwerp, Belgium.

22. Carl-Jacob Holmberg, Jan Mattsson, Roger Olofsson Bagge. Effects of the introduction of immunotherapy on isolated limb perfusion for metastatic melanoma. 42nd Congress of the European Society of Surgical Oncology (ESSO), 25–27 Oct 2023, Florence, Italy.
23. Ann-Sophie Lindqvist Bagge, Dimitrios Katsarelias, Roger Olofsson Bagge. Quality of life in patients with in-transit metastases of malignant melanoma. 39th Congress of the European Society of Surgical Oncology (ESSO), 9–11 Oct 2019, Rotterdam, The Netherlands.
24. Roger Olofsson Bagge, Peter Carlson, Jan Mattsson. Minimally-invasive isolated limb perfusion (MI-ILP) – a first report of a new technique. 39th Congress of the European Society of Surgical Oncology (ESSO), 9–11 Oct 2019, Rotterdam, The Netherlands.
25. Balsay-Patel C, Dugan MM, Wong A, Fan W, Kim Y, Ahmed A, Olofsson Bagge R\*, Zager JS\*. Percutaneous vs Isolated Hepatic Perfusion for Metastatic Uveal Melanoma: A Propensity Score-Matched Analysis. Podium presentation. Advanced Cancer Therapies Annual Meeting, 14–16 Feb 2026, Fort Lauderdale, Florida, USA.
26. Dugan MM, Balsay-Patel C, Wong A, Fan W, Kim Y, Ahmed A, Olofsson Bagge R\*, Zager JS\*. Percutaneous vs Isolated Hepatic Perfusion for Metastatic Uveal Melanoma: A Propensity Score-Matched Analysis. Podium presentation. Society of Surgical Oncology Annual Meeting, 5–7 Mar 2026, Phoenix, Arizona, USA.
27. Balsay-Patel C, Farooq MS, Dugan MM, Chin N, Israeli J, Leong SP, Olofsson Bagge R, Kashani-Sabet M, White Jr RL, Vetto JT, Schneebaum S, Howard JH, Avisar E, Namm JP, Kosiorek H, Pockaj B, Orcutt S, Crystal JS, Faries M, Hieken TJ, Karakousis GC, Zager JS, O'Donoghue C. Survival and recurrence outcomes for stage IIB/IIC melanoma: risk stratification for immunotherapy and surveillance. Quick shot presentation. Society of Surgical Oncology Annual Meeting, 5–7 Mar 2026, Phoenix, Arizona, USA.
28. Balsay-Patel C, Farooq MS, Dugan MM, Chin N, Israeli J, Leong SP, Olofsson Bagge R, Kashani-Sabet M, White Jr RL, Vetto JT, Schneebaum S, Howard JH, Avisar E, Namm JP, Kosiorek H, Pockaj B, Orcutt S, Crystal JS, Faries M, Hieken TJ, Karakousis GC, Zager JS, O'Donoghue C. Survival and recurrence outcomes for stage IIB/IIC melanoma: risk stratification for immunotherapy and surveillance. Poster presentation. Advanced Cancer Therapies Annual Meeting, 14–16 Feb 2026, Fort Lauderdale, Florida, USA.
29. UV-mutational signal metrics as predictors of melanoma specific survival. Kerryn Elliott, Linnea Ögren, Nazia Riaz, Sri Harsha Meghadri, Alice Schiller, Ka-Wei Tang, Anders Ståhlberg, Roger Olofsson Bagge, Erik Larsson. EMBL Conference, 11–14 Nov 2025, Heidelberg, Germany.
30. Analysis of ctDNA for early detection of relapse in patients with stage III–IV cutaneous melanoma receiving adjuvant PD-1 inhibitor therapy. Anna Fager, Kerryn Elliot, Henrik Jespersen, Peter Micallef, Kina Höglund, Roger Olofsson Bagge, Erik Lekholm Larsson, Anders Ståhlberg, Lars Ny. Nordic Melanoma Meeting, 10–12 Nov 2025, Tromsø, Norway.
31. Michelle M. Dugan, Danielle K. DePalo, Syeda Mahrukh Hussnain Naqvi, David W. Ollila, Tina J. Hieken, Matthew S. Block, Winan J. van Houdt, Sophie J. M. Reijers, Nethanel Asher, Kristy K. Broman, Hayden Snow, Jeffrey M. Farma, John T. Vetto, Madison Kolbow, Robyn P. M. Saw, Georgina V. Long, Lars Ny, Alexander C. J. Van Akkooi, Roger Olofsson Bagge, Jonathan S. Zager. A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases. Advanced Cancer Therapies, 14–17 Feb 2025, Scottsdale, Arizona, USA.
32. Jacob Israeli, Michelle M. Dugan, Nicholas Chin, Caitlyn Balsay-Patel, Anne Huibers, Wenyi Fan, Roger Olofsson Bagge, Jonathan S. Zager. Isolated limb infusion/perfusion for unresectable acral versus non-acral melanoma in-transit metastases. Advanced Cancer Therapies, 14–17 Feb 2025, Scottsdale, Arizona, USA.
33. Roger Olofsson Bagge. Minimal-invasive isolated limb perfusion. Advanced Cancer Therapies, 14–17 Feb 2025, Scottsdale, Arizona, USA.
34. Michelle M. Dugan, Aleena Boby, Helana Ghali, Shaliz Aflatooni, Danielle K. DePalo, Anne Huibers, Wenyi Fan, Roger Olofsson Bagge, Jonathan S. Zager. Isolated Limb Infusion or Perfusion as First-Line vs Second-Line or Later Therapy for Melanoma with In-Transit Metastasis. The 21st International Congress of the Society for Melanoma Research (SMR), 10–13 Oct 2024, New Orleans, Louisiana, USA.

35. W. Yu, A. Pazhava, M. Weitemeyer, L. Rosenkrantz, Iva Johansson, Roger Olofsson Bagge, J. Utikal, S. Venna, J. Jackson, T. Amaral, M. Egger, A. Meves. CP-GEP Identifies T1a Melanoma Patients At Risk of Sentinel Lymph Node Metastasis. The 21st International Congress of the Society for Melanoma Research (SMR), 10–13 Oct 2024, New Orleans, Louisiana, USA.
36. Axel Nelson, Amir Shafazand, Charlotta All-Ericsson, Christian Cahlin, Nils Elander, Hildur Helgadóttir, Jens Folke Kiilgaard, Sara Kinhult, Ingrid Ljuslinder, Magnus Rizell, Malin Sternby Eilard, Gustav Ullenhag, Jonas A. Nilsson, Lars Ny, Per Lindnér, Roger Olofsson Bagge. Long-term overall survival after isolated liver perfusion with melphalan in patients with isolated liver metastases of uveal melanoma (SCANDIUM trial). Kirurgveckan, 19–23 Aug 2024, Karlstad, Sweden.
37. Axel Nelson, Amir Shafazand, Charlotta All-Ericsson, Christian Cahlin, Nils Elander, Hildur Helgadóttir, Jens Folke Kiilgaard, Sara Kinhult, Ingrid Ljuslinder, Magnus Rizell, Malin Sternby Eilard, Gustav Ullenhag, Jonas A. Nilsson, Lars Ny, Per Lindnér, Roger Olofsson Bagge. A phase I randomized controlled multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (SCANDIUM II trial). Kirurgveckan, 19–23 Aug 2024, Karlstad, Sweden.
38. Leda Pistiolis, Sahar Alawieh, Thorhildur Halldorsdóttir, Anikó Kovács, Roger Olofsson Bagge. Melatonin MT1 receptor expression in luminal invasive ductal breast carcinoma in postmenopausal women. Kirurgveckan, 19–23 Aug 2024, Karlstad, Sweden.
39. Teresa Amaral, Stephan Forchhammer, Eftychia Chatziioannou, Iva Johansson, Eduardo Nagore, Esperanza Manrique-Silva, Víctor Través-Zapata, Barbara van Leeuwen, Marnix R. Jansen, Jose Bañuls, Noelia Jara-Rico, María Niveiro de Jaime, Ann-Sophie Bohne, Jüri Teras, Merrick I. Ross, Alexander van Akkooi, Jeffrey S. Weber, Dirk Schadendorf, Roger Olofsson Bagge, Axel Hauschild. Clinical validation of a prognostic 7-marker IHC assay (7-IHC) in 382 patients with stage IB/IIA cutaneous melanoma (MELARISK-001 study). ASCO Annual Meeting, 31 May–4 Jun 2024, Chicago, Illinois, USA (J Clin Oncol 42, 2024 suppl 16; abstr 9572).
40. Axel Nelson, Amir Shafazand, Christian Cahlin, Ana Carneiro, Hildur Helgadóttir, Max Levin, Magnus Rizell, Gustav J. Ullenhag, Sara Wirén, Per Lindnér, Jonas A. Nilsson, Lars Ny, Roger Olofsson Bagge. Overall survival after isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (SCANDIUM II trial). ASCO Annual Meeting, 31 May–4 Jun 2024, Chicago, Illinois, USA (J Clin Oncol 42, 2024 suppl 16; abstr 9533).
41. Axel Nelson, Amir Shafazand, Charlotta All-Eriksson, Christian Cahlin, Nils Elander, Hildur Helgadóttir, Jens Folke Kiilgaard, Sara Kinhult, Ingrid Ljuslinder, Jan Erik Mattsson, Magnus Rizell, Malin Sternby Eilard, Gustav J. Ullenhag, Jonas A. Nilsson, Lars Ny, Per Lindnér, Roger Olofsson Bagge. Long-term overall survival after isolated liver perfusion with melphalan in patients with isolated liver metastases of uveal melanoma (SCANDIUM trial). ASCO Annual Meeting, 31 May–4 Jun 2024, Chicago, Illinois, USA (J Clin Oncol 42, 2024 suppl 16; abstr 9532).
42. Anna Constantinescu, et al. Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis. ASCO Annual Meeting, 30 May–3 Jun 2025, Chicago, Illinois, USA.
43. Måns Kadefors, et al. Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab. ASCO Annual Meeting, 30 May–3 Jun 2025, Chicago, Illinois, USA.
44. Måns Kadefors, et al. The prognostic and predictive value of the immunological gene signatures interferon gamma and TIDE for patients with liver metastases from uveal melanoma treated with isolated hepatic perfusion. ASCO Annual Meeting, 30 May–3 Jun 2025, Chicago, Illinois, USA.
45. Axel Nelson, et al. Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: a Swedish retrospective real-world study (NEO-MEL). ASCO Annual Meeting, 30 May–3 Jun 2025, Chicago, Illinois, USA.

46. Hildur Helgadóttir, et al. Overall survival after the introduction of adjuvant treatment in stage III melanoma: a nationwide registry based study. ASCO Annual Meeting, 2–6 Jun 2023, Chicago, Illinois, USA.
47. Roger Olofsson Bagge, et al. Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (SCANDIUM trial). ASCO Annual Meeting, 3–7 Jun 2022, Chicago, Illinois, USA.
48. Roger Olofsson Bagge, et al. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: a multicenter cohort study. ASCO Annual Meeting, 3–7 Jun 2022, Chicago, Illinois, USA.
49. Piyush Grover, et al. Efficacy of adjuvant therapy in patients with AJCC v8 stage IIIA cutaneous melanoma. ASCO Annual Meeting, 2–6 Jun 2023, Chicago, Illinois, USA.
50. Danielle K. DePalo, et al. Intralesional therapy, limb infusion/perfusion, and immune checkpoint inhibitors as first-line therapy in surgically unresectable melanoma in-transit metastases. ASCO Annual Meeting, 2–6 Jun 2023, Chicago, Illinois, USA.
51. Rasmus Mikiver, et al. Population-based validation of the melanoma institute australia (MIA) and the memorial sloan-kettering cancer center (MSKCC) predictive tool for sentinel node status in patients with melanoma. ASCO Annual Meeting, 2–6 Jun 2023, Chicago, Illinois, USA.
52. Roger Olofsson Bagge, et al. A phase I, randomized, controlled, multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (SCANDIUM 2 trial). ASCO Annual Meeting, 2–6 Jun 2023, Chicago, Illinois, USA.
53. Roger Olofsson Bagge, et al. Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: results from a randomized controlled trial (SCANDIUM trial). ASCO Annual Meeting, 2–6 Jun 2023, Chicago, Illinois, USA.
54. Anna Constantinescu, Roger Olofsson Bagge, Anne Huibers. Can immunological phenotype predict response after isolated limb perfusion for patients with in-transit metastasis of melanoma? Swedish Surgical Week (Kirurgveckan), 18–22 Aug 2025, Linköping, Sweden.
55. Laila Azemovic, Jonas Manjer, Nushin Mirzaei, Anke Christenhusz, Andreas Karakatsanis, Stefan Eriksson, Fredrik Wärnberg, Roger Olofsson Bagge, et al. Magnetic sentinel lymph node biopsy in early melanoma and neoadjuvant immunotherapy: a feasibility study. Swedish Surgical Week (Kirurgveckan), 18–22 Aug 2025, Linköping, Sweden.
56. Ellen Krabbe, Axel Nelson, Karl Björkström, Anne Huibers, Christian U. Ullenhag, Hildur Helgadóttir, Lars Ny, Roger Olofsson Bagge. Neoadjuvant immunotherapy for patients with resectable melanoma. Swedish Surgical Week (Kirurgveckan), 18–22 Aug 2025, Linköping, Sweden.
57. Andrew Wong, Anne Huibers, Roger Olofsson Bagge. Percutaneous hepatic perfusion treatment for liver-dominant metastatic uveal melanoma. Swedish Surgical Week (Kirurgveckan), 18–22 Aug 2025, Linköping, Sweden.
58. Analysis of ctDNA for early detection of relapse in patients with stage III–IV cutaneous melanoma receiving adjuvant PD-1 inhibitor therapy. Anna Fager, Kerryn Elliott, Henrik Jespersen, Peter Micallef, Kina Höglund, Roger Olofsson Bagge, Erik Lekholm Larsson, Anders Ståhlberg, Lars Ny. Nordic Melanoma Meeting, 10–12 Nov 2025, Tromsø, Norway.
59. Serigne Lo, Caroline Gjorup, Annette Hougaard Chakera, Lisbet Rosenkrantz Hölmich, Marc Moncrieff, Alistair Ross, Oliver Cassell, Jiawen Ma, Roger Olofsson Bagge, Eduardo Bertolli, Cimarron Sharon, Giorgos C. Karakousis, Mohammed Kashani-Sabet, George Adigbli, Richard Scolyer, John Thompson, Alexander H. Varey. International validation study of the Melanoma Institute Australia sentinel node metastasis risk nomogram. Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, 22–25 Mar 2023, Boston, Massachusetts, USA.
60. Jenny Heiman, John Pavia, David Bock, Eva Haglind, Roger Olofsson Bagge. Predictive factors for sick leave at 12 months after breast cancer surgery in the randomized controlled physical activity trial (PhysSURG-B). Swedish Surgical Week (Kirurgveckan), 21–25 Aug 2023, Örebro, Sweden.
61. Fredrik Wärnberg, Kian Chin, Amalia Landén, Anikó Kovács, Maria Ekholm, Per Karlsson, Roger Olofsson Bagge. Tumor-infiltrating lymphocytes (TILs) as predictor of complete

- pathological response (pCR) for invasive breast cancers with axillary metastases (cN+). Swedish Surgical Week (Kirurgveckan), 21–25 Aug 2023, Örebro, Sweden.
62. Fredrik Wärnberg, Roger Olofsson Bagge, Nushin Mirzaei, Anikó Kovács, Henrik Leonhardt, Pontus Zaar, Eirini Pantiora, Maria Ekholm, Staffan Eriksson, Andreas Karakatsanis, Kian Chin. Targeted axillary dissection (TAD) and sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy: the SentiNeo pilot study. Swedish Surgical Week (Kirurgveckan), 21–25 Aug 2023, Örebro, Sweden.
  63. Slavica Janeva, Toshima Z. Parris, Ellen Krabbe, Marie Sundquist, Per Karlsson, Riccardo A. Audisio, Roger Olofsson Bagge, Anikó Kovács. Clinical relevance of biomarker discordance between primary breast cancers and synchronous axillary lymph node metastases. Swedish Surgical Week (Kirurgveckan), 21–25 Aug 2023, Örebro, Sweden.
  64. I. Johansson, D. Tempel, J.T. Dwarkasing, B. Rentroia-Pacheco, J. Mattsson, L. Ny, Roger Olofsson Bagge. Independent validation study of CP-GEP model (Merlin Assay) to identify patients who can safely forgo sentinel lymph node biopsy. EADO Congress, 2021.
  65. Roger Olofsson Bagge. Minimal-invasive isolated limb perfusion. Advanced Cancer Therapies Annual Meeting, 14–17 Feb 2025, Scottsdale, Arizona, USA.
  66. Michelle M. Dugan, Danielle K. DePalo, Syeda Mahrukh Hussnain Naqvi, David W. Ollila, Tina J. Hieken, Matthew S. Block, Winan J. van Houdt, Sophie J.M. Reijers, Nethanel Asher, Kristy K. Broman, Hayden Snow, Jeffrey M. Farma, John T. Vetto, Madison Kolbow, Robyn P.M. Saw, Georgina V. Long, Lars Ny, Alexander C.J. van Akkooi, Roger Olofsson Bagge, Jonathan S. Zager. A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases. Advanced Cancer Therapies Annual Meeting, 14–17 Feb 2025, Scottsdale, Arizona, USA.
  67. Jacob Israeli, Michelle M. Dugan, Nicholas Chin, Caitlyn Balsay-Patel, Anne Huibers, Wenyi Fan, Roger Olofsson Bagge, Jonathan S. Zager. Isolated limb infusion/perfusion for unresectable acral versus non-acral melanoma in-transit metastases. Advanced Cancer Therapies Annual Meeting, 14–17 Feb 2025, Scottsdale, Arizona, USA.
  68. H. Jespersen, Roger Olofsson Bagge, L. Ny. Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study). ESMO Congress, 27 Sep–1 Oct 2019, Barcelona, Spain.
  69. S. Ahlstedt Karlsson, Roger Olofsson Bagge, C. Wallengren. Experiences of endocrine therapy after breast cancer surgery. ESMO Congress, 27 Sep–1 Oct 2019, Barcelona, Spain.
  70. K. Broman, T.M. Hughes, L.A. Dossett, J. Sun, D. Kirichenko, M.J. Carr, T.J. Hieken, L. Kottschade, J. Downs, D.E. Gyorki, D. Ollila, J. Frank, Y. Song, G.C. Karakousis, J. Vetto, D. Han, J. Deneve, M. Fleming, Roger Olofsson Bagge, J. Mattsson, A.Y. Lee, R.S. Berman, H. Chai, H.M. Kroon, R.M. Teras, J. Teras, N.E. Farrow, G.M. Beasley, J. Hui, L. Been, S. Kruijff, Y. Kim, S.M. Naqvi, M. Perez, M.C. Lowe, A.A. Sarnaik, V.K. Sondak, J.S. Zager. Active surveillance of melanoma patients with sentinel node metastasis: an international multi-institution evaluation of post-MSLT-2 adoption and early outcomes. Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, 25–28 Mar 2020, Boston, Massachusetts, USA.
  71. M.D. Moncrieff, S. Lo, R. Scolyer, J. Nobes, M. Heaton, A. Snelling, M.J. Carr, J.S. Zager, R. Kisyova, J. Mason, E. Wilson, R. Wade, H. Peach, C. Nessim, G. Nolan, R. Pritchard-Jones, Roger Olofsson Bagge, I. Johansson, L. Wright, N. Patel, V.K. Sondak, J.F. Thompson. A quest for the lost tribe: surgical management of AJCC IB melanoma with the advent of adjuvant systemic therapy. Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care (Virtual Meeting), 18–19 Mar 2021.
  72. D. Gyorki, M.D. Moncrieff, R.P. Saw, A.J. Spillane, Roger Olofsson Bagge, F. Wright, J. Dancy, J.M. Mammen, E. Paton, N. Williams, D. Seminara, J. Eguchi, M.A. Henderson. Melanoma margins trial (MelMarT-II): a framework for global recruitment to a large multicentre multinational randomised controlled trial. Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care (Virtual Meeting), 18–19 Mar 2021.
  73. Lea-Anne Harrison, Marc D. Moncrieff, Sandra Vargas, Tiiu Sildva, Roger Olofsson Bagge, Karolin Isaksson, David E. Gyorki, Robyn P. Saw, Andrew J. Spillane, Frances C. Wright, Janet Dancy, Joshua M. Mammen, Richard Martin, James van Bastelaar, Shirley Potter,

Michael A. Henderson. Melanoma margins trial (MelMarT-II) evaluating 1 cm vs 2 cm wide local excision margins for patients with primary cutaneous melanomas. Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, 9–12 Mar 2022, Dallas, Texas, USA.

74. Carl Jacob Holmberg, Rasmus Mikiver, Karolin Isaksson, Kari Nielsen, Christian Ingvar, Johan Lyth, Roger Olofsson Bagge. Sentinel node biopsy in cutaneous melanoma is an important prognostic factor also in thick melanomas. Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, 9–12 Mar 2022, Dallas, Texas, USA.
75. UV-mutational signal metrics as predictors of melanoma specific survival. Kerryn Elliott, Linnea Ögren, Nazia Riaz, Sri Harsha Meghadri, Alice Schiller, Ka-Wei Tang, Anders Ståhlberg, Roger Olofsson Bagge, Erik Larsson. EMBL Conference, 11–14 Nov 2025, Heidelberg, Germany.
76. Anna Constantinescu, et al. Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis. ASCO Annual Meeting, 30 May–3 Jun 2025, Chicago, Illinois, USA.
77. Måns Kadefors, et al. Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab. ASCO Annual Meeting, 30 May–3 Jun 2025, Chicago, Illinois, USA.

---

## RESEARCH GRANTS AND AWARDS

---

I have received and are currently receiving national funding from the major Swedish funders (Vetenskapsrådet, Cancerfonden, Knut och Alice Wallenberg and Sjöbergstiftelsen) as well as an international grant from American Associated for Cancer Research. I also have ALF-funding and receive support from regional funders such as Assar Gabrielsson and Gothenburg Medical Association

### RESEARCH FUNDING IN INTERNATIONAL/NATIONAL COMPETITION

#### Principal applicant

2025	The Sjöberg Foundation (2026-28)	3 000 000 SEK
2025	Swedish Cancer Society (25 4339 Pj) (2025)	1 000 000 SEK
2025	Swedish Research Council (2025-03049) (2026-29)	4 500 000 SEK
2024	Swedish Research Council (2024-00229) (2024-28)	15 667 590 SEK
2024	Swedish Cancer Society (24 3365 S) (2025-2)	7 000 000 SEK
2024	Nordic Cancer Union (R281-A16044) (2025)	3 300 000 SEK
2023	Swedish Society for Medical Research Consolidator grant (CG-23-0056-B)	11 000 000 SEK
2023	WCMTM, Paired Post-Doc (2020-23)	3 500 000 SEK
2022	Swedish Cancer Society (22-2265) (2023-25)	3 000 000 SEK
2021	The Sjöberg Foundation (2022-24)	4 500 000 SEK
2021	AACR-Ocular Melanoma Foundation Award (21-20-39) (2021-22)	750 000 SEK
2020	Swedish Research Council (2020-02446) (2022-24)	6 000 000 SEK
2020	Assar Gabrielsson foundation (BGR20-02) (2020-21)	600 000 SEK
2019	Swedish Cancer Society (19-0040) (2020-22)	2 400 000 SEK
2019	Wallenberg Center for Molecular and Translational Medicine (2020-23)	12 000 000 SEK

### OTHER RESEARCH FUNDING

#### Principal applicant

2025	NHV Region Västra Götaland (NHV-1026496) (2026)	300 000 SEK
2024	Erik och Lily Philipsons Stiftelse	400 000 SEK
2024	Swedish state ALF-agreement (ALFGBG-1005121) (2025-27)	5 250 000 SEK
2024	Swedish state ALF-agreement (Prova på forskning Ellen Krabbe)	300 000 SEK
2023	PostDoc WCMTM Alumni (2024-26)	2 550 000 SEK
2023	Erik och Lily Philipsons Stiftelse	500 000 SEK
2023	Sahlgrenska Comprehensive Cancer Center	250 000 SEK
2023	WCMTM Paired PostDoc	3 500 000 SEK
2022	Postdoctoral position at Sahlgrenska Academy (2023-2024)	2 550 000 SEK

2022	NHV Region Västra Götaland (NHV-977897) (2023-24)	600 000 SEK
2021	Swedish state ALF-agreement (ALFGBG-965024) (2022-24)	3 000 000 SEK
2019	Swedish state (ALF-agreement) Klinisk behandlingsforskning	1 500 000 SEK
2019	Swedish Cancer Foundation (19 0040 Pj) (2020-203)	2 400 000 SEK
2019	Wallenberg Center for Molecular and Translational Medicine	12 000 000 SEK
2018	Region Västra Götaland – Developing ILP (2018-19)	1 000 000 SEK
2018	Assar Gabrielsson foundation (2018)	50 000 SEK
2018	Gothenburg Medical Association (785821) (2018)	50 000 SEK
2018	Gothenburg Medical Association (782781) (2018)	100 000 SEK
2018	Gothenburg Medical Association (779001) (2018)	100 000 SEK
2017	Swedish state (ALF-agreement grant number 77990) (2017-20)	1 400 000 SEK
2017	Swedish state (ALF-agreement grant number 718921) (2017-20)	400 000 SEK
2017	Gothenburg research council (703271) (2017)	105 000 SEK
2016	Gothenburg Medical Association (587311) (2016)	100 000 SEK
2015	Swedish state (ALF-agreement grant number 77990) (2017-20)	1 400 000 SEK
2015	Aina Wallströms and Mary-Ann Sjöbloms foundation (2015)	50 000 SEK
2015	Assar Gabrielsson foundation (2015)	67 000 SEK
2015	Gothenburg Medical Association (497141) (2015)	100 000 SEK
2015	Karl and Annie Leons Memorial Fund (2015)	50 000 SEK
2014	Assar Gabrielsson foundation (2014)	72 000 SEK
2013	Signe och Olof Wallenius stiftelse	75 000 SEK
2013	Gothenburg Medical Association (326971) (2013)	70 000 SEK
2010	Gothenburg Medical Association (98811) (2010)	70 000 SEK

#### **Co-applicant**

2018	Regional Research Council Västra Götalandsregionen (856341)	234 000 SEK
2018	Swedish state (ALF-agreement grant number 826061)	400 000 SEK
2017	Swedish state (ALF-agreement grant number 719301)	500 000 SEK
2017	Swedish state (ALF-agreement grant number 725911)	1 500 000 SEK
2017	Regional Research Council Västra Götalandsregionen (759671)	279 000 SEK
2015	Swedish Medical Association (497891)	150 000 SEK
2014	Swedish state (ALF-agreement grant number 432481)	1 725 000 SEK
2014	Swedish state (ALF-agreement grant number 434331)	975 000 SEK
2014	Swedish state (ALF-agreement grant number 434691)	725 000 SEK
2014	Swedish state (ALF-agreement grant number 444911)	1 375 000 SEK

---

## **SCIENTIFIC WORK**

---

#### **CLINICAL TRIALS**

2025	Principal investigator of the international multicenter MARIANE trial (NCT06240143)
2025	Principal investigator of the international multicenter PHP-MBC-202 trial (NCT06875128)
2025	Principal investigator of the Swedish NEOPRIME RCT (NCT06519266)
2025	Co-investigator of the international multicenter WiseVsWide RCT (NCT06363591)
2024	Principal investigator of the international multicenter SCANDIUM-III RCT (NCT06519266)
2021	Principal investigator of the Swedish MAGSNOW RCT (NCT05359783)
2021	Principal investigator of the Swedish multicenter SCANDIUM-II RCT (NCT04463368)
2020	Principal investigator of the Swedish multicenter SUMMIST RCT (NCT04242329)
2020	Co-investigator (Nordic countries) of the international multicenter MelMart-II RCT (NCT03860883)
2020	Principal investigator of the Swedish MAGMEN trial (NCT03898687)
2019	Co-investigator of the international multicenter EORTC 1617-QLG-BCG-ROG trial (NCT03859453)
2019	Principal investigator of the Swedish MI-ILP trial (NCT03376126)
2018	Principal investigator of the international multicenter Nivo-ILP RCT (NCT03685890)
2017	Co-investigator of the Swedish multicenter trial TRIM (NCT03116412)

- 2014 Co-investigator of the international multicenter MelMart RCT (NCT02385214)
- 2014 Principal investigator of the Swedish multicenter PhysSurg-B RCT (NCT02560662)
- 2013 Principal investigator of the international multicenter SCANDIUM RCT (NCT01785316)
- 2013 Co-investigator of the international multicenter BIG 1-98 (IBCSG 18/98) RCT (NCT00004205)
- 2013 Co-investigator of the international multicenter IBCSG-28 study HERA RCT (NCT00045032)
- 2013 Co-investigator of the international multicenter IBCSG 35-07 SOLE RCT (NCT00553410)
- 2013 Co-investigator of the international multicenter ABCSG 18 Denosumab RCT (NCT00556374)
- 2013 Co-investigator of the international multicenter SweBCG SenoMac RCT (NCT02240472)

#### ACTIVE NATIONAL SCIENTIFIC COLLABORATIONS

- 2013- Swedish Breast Cancer Study Group (SweBCG)
- 2012- Sahlgrenska Translational Melanoma Group (SATMEG).
- 2011- Swedish Melanoma Study Group (SMSG)

#### ACTIVE INTERNATIONAL SCIENTIFIC COLLABORATION GROUPS

- 2021- International Neoadjuvant Melanoma Consortium (INMC)
- 2020- Sentinel Lymph Node Working Group (SLNWG)
- 2019- European Organization for Research and Treatment of Cancer (EORTC)
- 2016- The Australia and New Zealand Melanoma Trials Group (ANZMTG).

---

### SUPERVISION OF RESEARCH

---

#### Finalized PhD-projects

I have been the main supervisor for the following PhD thesis projects:

1. Valerio Belgrano, University of Gothenburg, thesis presented 2019-06-04  
*Development of individualized surgical treatments for malignant melanoma*
2. Jenny Heiman, University of Gothenburg, thesis presented 2021-12-10  
*Breast cancer surgery – Aspects of patient-reported outcomes and physical activity*
3. Carl Jacob Holmberg, University of Gothenburg, thesis presented 2024-02-23  
*Melanoma surgery in the era of modern immunotherapy*
4. Nushin Mirzaei, University of Gothenburg, thesis presented 2024-05-24  
*Superparamagnetic iron oxide for sentinel lymph node biopsy*
5. Anna Corderfeldt, University of Gothenburg, thesis presented 2024-05-31  
*Oxygen demand and neuronal biomarker release during extracorporeal circulation*

I have been assistant supervisor for the following PhD thesis projects:

6. Kian Chin, Gothenburg University, thesis presented 2026-01-23 *Advancing surgical strategies for breast cancer in the era of neoadjuvant chemotherapy*
7. Slavica Janeva, Gothenburg University, thesis presented 2023-05-26 *Clinical significance of immunohistochemistry in breast cancer diagnostics*
8. Iva Johansson, Gothenburg University, thesis presented 2022-12-14 *Studies of molecular features and novel prognostic biomarkers of cutaneous melanoma*
9. Susanne Ahlstedt Karlsson, Gothenburg University, thesis presented 2022-05-20 *Designing, developing, and evaluating a person-centered support model for women with breast cancer treated with endocrine therapy*
10. Elin Forsberg, University of Gothenburg, thesis presented 2020-01-10  
*Novel immunotherapies for metastatic melanoma - from mouse models towards clinical trials*
11. Junko Johansson, University of Gothenburg, thesis presented 2019-05-29  
*Immunological effects of isolated regional perfusion in malignant melanoma*

I have been the main supervisor for the following Postdoc projects:

1. Emma Symonds, Gothenburg University (2024-2025)
2. Lijuan Yu, Gothenburg University (2024-2025)

I have been the assistant supervisor for the following Postdoc projects:

1. Elodie Barthout, Gothenburg University (2024-2025)

#### **Ongoing PhD-projects**

1. Main supervisor Marcus Nuyberg, University of Gothenburg
2. Main supervisor Ellen Krabbe, University of Gothenburg
3. Main supervisor Andrew Wong, University of Gothenburg
4. Main supervisor Lida Pistoli, University of Gothenburg
5. Assistant supervisor Georgios Panagiotis Sigalas, University of Gothenburg
6. Assistant supervisor Astrid Nilsson Ek, University of Gothenburg
7. Assistant supervisor Anna Arheden, University of Gothenburg
8. Assistant supervisor Pontus Zaar, University of Gothenburg
9. Assistant supervisor Michail Zoulakis, University of Gothenburg
10. Assistant supervisor Carl Hallin, University of Gothenburg

#### **Ongoing PostDoc supervision**

2. Main supervisor Anne Huibers, University of Gothenburg (2024-2026)
3. Main supervisor Måns Kadefors, University of Gothenburg (2024-2026)
4. Main supervisor Nazia Riaz, University of Gothenburg (2024-2026)

#### **Finalized Master thesis-projects**

1. Main supervisor Sonia Alvi (2022), University of Gothenburg
2. Main supervisor Jonas Rickard Wennermark (2021), University of Gothenburg
3. Main supervisor Anna Corderfeldt (2017), University of Gothenburg
4. Main supervisor Andreas Wendt Nyström (2016), University of Gothenburg
5. Main supervisor Ilan-Ben Shabat (2015), University of Gothenburg

#### **Finalized resident research projects**

1. Main supervisor Olöf Margaretardottir (2018), University of Gothenburg
2. Main supervisor Thorhildur Halldorsdottir (2016), University of Gothenburg
3. Main supervisor Jessica Pettersson (2016), University of Gothenburg
4. Main supervisor Jenny Heiman (2015), University of Gothenburg

#### **Clinical research fellow**

1. Main supervisor Sophie Orme (2026), Norwich, United Kingdom
2. Main supervisor Martijn Betlehem (2021), Groningen, Netherlands

---

## **ASSESSMENT OF THE WORKS OF OTHERS**

---

#### **REVIEW OF DISSERTATION WORK**

##### **Faculty examiner (opponent)**

- |                 |                                       |
|-----------------|---------------------------------------|
| 2025 PhD-thesis | Sanni Tulokas, University of Helsinki |
| 2018 PhD-thesis | Åsa Wickberg, Örebro University       |

##### **Chairman of the Examination Committee**

- |                        |  |
|------------------------|--|
| 2022 PhD-thesis        | Loius Szeponik, Gothenburg University        |
| 2021 PhD-thesis        | Sara Fischer, Gothenburg University          |
| 2020 PhD-thesis        | Kristian Axelsson, Gothenburg University     |
| 2020 Half-time seminar | Mikael Barbu, Gothenburg University          |
| 2020 PhD-thesis        | Fernando Ruiz, Gothenburg University         |
| 2019 Half-time seminar | Karolin Berger, Gothenburg University        |
| 2018 PhD-thesis        | Sukhi Singh, Gothenburg University           |
| 2018 PhD-thesis        | Anna-Karin Elf, Gothenburg University        |
| 2018 PhD-thesis        | Zsuzsa Ingulf Bartiks, Gothenburg University |
| 2018 Half-time seminar | Kristian Smidfeldt, Gothenburg University    |
| 2018 PhD-thesis        | Tobias Nilsson, Gothenburg University        |

2018 PhD-thesis Ellen Johansson, Gothenburg University  
2018 PhD-thesis Carina Ejdeholm, Gothenburg University  
2018 PhD-thesis Oscar Zaar, Gothenburg University  
2017 Half-time seminar Madiha Bhatti Söftelands, Gothenburg University

#### **Member of the Examination Committee**

2018 PhD-thesis Martin Sjöström, Lund University  
2017 PhD-thesis Gustav Stålhammar, Karolinska Institute

#### **External reviewer**

2018 PhD-thesis Nyan Khin, Macquarie University, Sydney, Australia

#### **REVIEW OF ACADEMIC POSITIONS**

2025 External evaluator of Professor of Surgery at Harvard Medical School, Boston, USA.

#### **REVIEW OF GRANT APPLICATIONS**

##### **Reviewer of national research applications**

2026- INTER-LOCAL European grants  
2026- Swedish Cancer Society (Cancerfonden prioriteringskommitté A3)  
2024- Swedish Research Council (Vetenskapsrådet MH-08)  
2022- Swedish Breast Cancer Foundation (Bröstcancerförbundet)  
2021-2022 Vinnova

##### **Reviewer of international research applications**

2022- External peer reviewer, National Institute for Health Research (NIHR), UK  
2021- Grant reviewer, Dutch Cancer Society (KWF), Netherlands  
2018- Grant reviewer, German Research Foundation, Germany

#### **EDITORIAL AND REVIEW**

##### **Editor**

2025 Advisor for the Editorial Board of the Journal of the Polish Oncological Society  
2025- Editorial Board member British Journal of Surgery (BJS)  
2025- Associate editor Annals of Surgical Oncology (ASO)  
2021- Associate editor European Journal of Surgical Oncology (EJSO)

##### **Member of Editorial Boards**

2024- British Journal of Surgery  
2020- Cancers  
2018- European Journal of Surgical Oncology (EJSO)

##### **Reviewer assignments**

I regularly perform reviews for Annals of Surgical Oncology, European Journal of Surgical Oncology, British Journal of Surgery, European Journal of Cancer, Lancet Oncology, Cancers, European Radiology, International Journal of Hyperthermia, Journal of the European Academy of Dermatology and Venerology, Pigment Cell & Melanoma Research, Journal of Plastic Surgery and Hand Surgery, Acta Oncologica, Journal of Surgical Oncology among others. I have performed a total of 138 verified reviews on WebOfScience.

#### **ORGANIZING NATIONAL OR INTERNATIONAL CONFERENCES**

2024- Member of the scientific organisation committee for the melanoma track, European Society of Medical Oncology (ESMO)  
2023- Member of the scientific organisation committee for the 10<sup>th</sup> International Congress on Cancer Metastasis through the Lymphovascular system, USA  
2025 President for the 44<sup>th</sup> European Society for Surgical Oncology (ESSO) meeting, Gothenburg, October 2025.

- 2018 President and head organizer of the State-of-the-Art Breast Cancer meeting (SOTA) 4-5 October in Gothenburg
- 2018- Member of the scientific organisation committee for the Breast and Melanoma part of the Swedish Surgical Week
- 2015 Organizer for the 11th Nordic Melanoma Meeting, September 2015, Gothenburg, Sweden
- 2013 Member of the organisation committee for the 26th European MusculoSkeletal Oncology Society Meeting (EMSOS) 29-31 May in Gothenburg

#### SCIENTIFIC AWARDS

- 2021 The Swedish Surgical Society Research Award (250.000SEK)
- 2021 AACR-Ocular Melanoma Foundation Career Development Award In Honor of Robert C. Allen, MD
- 2020 The Swedish Surgical Society Regional Research Award (Western region) (10.000SEK)
- 2019 Eva Selin Lindgrens Memorial Award (100.000SEK)
- 2019 The Swedish Surgical Society Regional Research Award (Western region) (10.000SEK)
- 2018 Best abstract. The Thirteenth International Symposium on Regional Cancer Therapies. February 14 - 16, 2015, Jacksonville, Florida, USA (5.000SEK)
- 2016 Best abstract. The Tenth International Symposium on Regional Cancer Therapies. February 14 - 16, 2015, Clearwater, Florida, USA (5.000SEK)
- 2015 Best abstract. The Tenth International Symposium on Regional Cancer Therapies. February 14 - 16, 2015, Clearwater, Florida, USA (5.000SEK)

---

### PEDAGOGIC ACADEMIC PORTFOLIO

---

#### Courses completed

- 2020 Teaching and Learning in Higher Education 3: Applied analysis (credited), 5 ECTS (HPE103). Gothenburg University.
- 2016 Teaching and Learning in Higher Education 1: Subject Field Pedagogy, 5 ECTS (HPE102). Gothenburg University.
- 2015 Teaching and Learning in Higher Education 1: Basic Course, 5 ECTS (HPE101). Gothenburg University.
- 2014 Supervision in Postgraduate Programmes, 5 ECTS (HPE201). Gothenburg University.

#### Qualifications required for appointment as a docent (reader)

- 2016 Docent in Surgery (2016-11-29), Gothenburg University.

#### Pedagogic awards

- 2013 Nominee *Supervisor of the year for interns*. Sahlgrenska University Hospital.
- 2012 Awarded *Supervisor of the year for interns*. Sahlgrenska University Hospital.
- 2011 Nominee *Supervisor of the year for interns*. Sahlgrenska University Hospital.
- 2010 Nominee *Supervisor of the year for interns*. Sahlgrenska University Hospital.
- 2010 Awarded "*Guldtackan*". A prize as the best educator for medical students at Gothenburg University.
- 2009 Nominee for "*Pedalenpriset*". The prize is awarded to teachers or teaching environments that in a meritorious manner conveyed knowledge and commitment to the students at Sahlgrenska Academy at Gothenburg University.
- 2009 Awarded "*Guldtackan*". A prize as the best educator for medical students at Gothenburg University.

---

### ADMINISTRATION OF TEACHING

---

#### Course coordinator

- 2021-present Course director, Clinical Cancer Research for PhD students, (SK00030, Third cycle, 1.5 ECT), Gothenburg University

- 2021-present Course co-director, Cancer Research South (CARES) School for PhD students (Third cycle), Gothenburg University and Lund University
- 2020-present Course co-director, Scientific Degree Project Thesis for Medicine students (10<sup>th</sup> semester), (LÄA110, Second cycle, 30 ECTS)
- 2014-2019 Course director, National course in Breast surgery for Surgical residents in Sweden (mandatory KUB-kurs). Postgraduate level. Swedish Surgical Society.
- 2005-2009 Course director, General medicine for Dental hygienist students (First cycle, 3 ECTS), Gothenburg University.
- 2007-2009 Course director, Physiology for Dental hygienist students (First cycle, 3 ECTS yearly), Gothenburg University.

#### **Administrative work within education**

- 2018-present Member of the steering group for Grand Rounds at Sahlgrenska University Hospital. Planning for four Grand Rounds per semester, approximately 10 hours.
- 2013-2019 Director for the *Swedish educational committee for breast cancer surgery*, Swedish Society of Breast Surgeons. Responsible for meetings, course development, administration, course evaluations and examination. Approximately six courses per year with approximately 40 hours of work

#### **Board, committee or other advisory work**

- 2020-present Member of the committee recommending the PhD-thesis of the year at Sahlgrenska Academy, Gothenburg University.
- 2020-present Member of a faculty board evaluating student applications for funding of e.g. studies in other countries (e.g. MFS-stipend)

#### **Course evaluations and course development**

- 2014-2019 I developed the mandatory national course in breast surgery for surgical residents in Sweden (KUB-kurs) for the Swedish Surgical Society. I created a framework for lectures including joint lectures independent on which hospital that hosted the course. I also developed standardized course examinations and course evaluations that have been used to continuously improve the courses at a national level.
- 2005-2009 I developed the course in General medicine for dental hygienist students (first cycle, 3 ECTS), including all lectures, examinations and course evaluations. The course evaluations were used to improve the course continuously over the semesters.
- 2007-2009 I developed the course in Physiology for dental hygienist students (First cycle, 3 ECTS yearly), including all lectures, examinations and course evaluations. The course evaluations were used to improve the course continuously over the semesters.

---

### **PRODUCTION OF TEACHING MATERIAL**

---

- 2019 Chapter on Melanoma surgery in the textbook “Kirurgi” editor Jeppsson. Studentlitteratur 2019. The chapter is aimed towards second cycle medical students to complete the theoretical knowledge about surgery for melanoma and other skin cancers. I inherited the chapter from professor Christian Ingvar, and have made a complete revision of the content.
- 2018 Article on internetmedicin on isolated limb perfusion. <https://www.internetmedicin.se/behandlingsoversikter/kirurgi/isolerad-hyperterm-perfusion-isolated-limb-perfusion-ilp/>
- 2015 Video: How to perform isolated liver perfusion (Journal of Visualized experiments, JoVE). I have developed the video myself, and the video has been used in several courses internationally to learn in detail how to perform this type of surgery (post-graduate level).
- 2014 Created the education in *Breast cancer and breast examination* at the Clinical Training Center at Gothenburg University where I developed a seminar for all medicine students during their surgical rotation to learn about breast cancer and how to examine patients

(second cycle). As a part of this I purchased standardized breast examination dolls with 6 different types of pathologies, which the students then examine in a standardized way.

---

## TEACHING EXPERIENCE

---

### Summary of teaching

	First cycle	Second cycle	Third cycle	Post-graduate
Lecturing	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Seminars	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Supervision		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Course development	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Course administration	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Examination			<input type="checkbox"/>	<input type="checkbox"/>

### Lecturer at first and second cycle level

- 2020-present Project plan seminars, Scientific Degree Project Thesis for Medicine students. 80 hours per year. In these seminars the students in groups of 6 present their project plan and I then guide the discussion on how to improve the plans. Second cycle. Gothenburg University.
- 2020-present Poster seminars, Scientific Degree Project Thesis for Medicine students. 16 hours per semester. In this seminar the students have prepared posters and in smaller groups I lead the discussion on each poster and what could have been done differently to convey the research message. Second cycle. Gothenburg University.
- 2016-present Lecture on Breast cancer for medical doctors outside of EU (KUL). 3 hours per semester. Second cycle. Gothenburg University.
- 2014-present Individual education in breast and melanoma surgery for medicine students where they attend my out-patient clinic. Approximately 32 hours per year. Second cycle. Gothenburg University.
- 2014-2018 Practical teaching in Breast cancer and breast examination at Clinical Training Center. 16 hours per year. Second cycle. Gothenburg University.
- 2006-2015 Practical teaching in seminar form, KUA-weeks (kandidat undervisningsavdelning), a week at a surgical ward with a small group of 3-4 students where I guided the students in performing rounds and other routine work at wards. Approximately 100 hours per year. Second cycle. Gothenburg University.
- 2005-2009 Lecture in General medicine for dental hygienist students. 115 hours in total. First cycle. Gothenburg University.
- 2007-2009 Lecture in Physiology for dental hygienist students. 69 hours in total. First cycle. Gothenburg University.

### Lecturer at third cycle level

- 2019- Lecturer in the PhD course Cancer Research South (CARES) School, both in seminars and online. Approx 4 hours per year.
- 2018 Lecture for PhD-students at Sahlgrenska Center for Cancer Research

### Continuing professional development

- 2025 Invited lecturer. "Regional cancer therapies". Seldinger honorary meeting. 22nd May 2025, Gothenburg, Sweden.
- 2025 Invited lecturer. "Kurativ behandling av melanom". Meeting arranged by MSD. 20<sup>th</sup> May 2025, Gothenburg, Sweden.
- 2025 Invited lecturer. "Metastaskirurgi vid melanom". Meeting arranged by BMS. 19th May 2025, Linköping, Sweden.
- 2025 Invited lecturer. "Brystkreft og melanom på agendaen". 3<sup>rd</sup> April 2025, Trondheim Norway.

2025	Invited lecturer. “Grand debate: Why ipi/nivo should be used as neoadjuvant treatment in melanoma“. Society of Surgical Oncology (SSO), 26-28 <sup>th</sup> of March 2025, Tampa, Florida, USA.
2025	Invited lecturer. “Liver Directed Treatments for Metastatic Uveal Melanoma“. European Society of Medical Oncology (ESMO), 20-22 <sup>nd</sup> of March 2025, Lugano, Switzerland.
2025	Invited lecturer. “Surgery after Neo-Adjuvant Treatment“. Danish Melanoma Group - Oncology Scientific Meeting, 15 <sup>th</sup> of January 2025, Odense, Denmark.
2024	Chair. European School of Oncology “Refresher Course in Melanoma Surgery”, 11-13 Oct, Dublin, Ireland
2021	Lecture “Melanoma surgery” at the Swedish Surgical Society meeting in Gothenburg, 1 hour.
2019	The Role of Surgeons in Treating Melanoma. Harvard Global Health Catalyst Win-Win Initiative. 1-hour lecture. Harvard Medical School, Boston, USA.
2019	Lecture “Melanoma surgery” at the Swedish Surgical Society meeting in Gothenburg, 1 hour.
2019	Advanced course in Melanoma Surgery (ESSO). 3 hours per year. European Society of Surgical Oncology.
2018	Webinar “ESSO Webinar: Controversies in Melanoma surgery: current evidence and practice”. European Society of Surgical Oncology. 2 hours.
2018	Lecture “Melanoma and staging –a surgeon’s perspective” for Roche. 3 hours. Gothenburg
2018	Lecture “Isolated limb perfusion” for the Norwegian health ministry. 1 hour.
2018	Lecture “Melanomkirurgi” during a symposium arranged by Läkartidningen. 1 hour.
2017	Lecture “Bröstkirurgi” for Regional Cancer West. 1 hour. Gothenburg.
2017	Lecture “Bröstkirurgi i dåtid, nutid och framtid” in a course for breast care nurses sponsored by Roche. 1 hour. October. Stockholm
2016-present	Advanced course in melanoma for Dermatologists. 1 hour per year. Sahlgrenska University Hospital.
2014-2019	Lecturer, National course in Breast surgery for Surgical residents in Sweden (mandatory KUB-course). 16 hours per year. Postgraduate level. Swedish Surgical Society.
2015	Lead the workshop on “Regional treatments” in the Nordic Melanoma Meeting, Gothenburg, 4 hours.
2014	Lecture on “Malignant melanoma”, at the SkinResQ seminar. Gothenburg University. 1 hour
2011	Lecture in a workshop on “How to perform isolated limb and liver perfusion”, Gothenburg Sweden. 4 hours

---

## MANAGEMENT/LEADERSHIP, ELECTED POSTS

---

### Commitments on boards, committees and work groups

2024-present	Member in the workgroup (WP10) of the European Union Joint Action on Networks of Expertise on Cancer (JANE2), European Commission.
2021-present	Member of the Sentinel Lymph Node Working Group (Los Angeles, USA)
2020-present	Member of the Election committee for the Swedish Surgical Society.
2020	Investigator concerning the centralization of isolated limb perfusion ”Nationell högspecialiserad vård”, National Board of Health and Welfare, Sweden.
2019-present	Board member, European Society of Medical Oncology (ESMO), European guidelines for melanoma treatment.
2019-present	Member of the EORTC Melanoma Group
2018-present	Member of European Organization for Research and Treatment of Cancer (EORTC)
2016-present	Editor of Swedish guidelines for melanoma surgery (Regional Cancer Center)
2016-2019	Secretary of the Swedish Breast Cancer Group (SweBCG)
2015-2019	Board member. Swedish Society for Breast Surgery (SFFB)

- 2014 Head of workgroup concerning centralization of isolated limb perfusion  
”Sakkunniggrupp för nationell nivåstrukturerad av isolerad hyperterm perfusion”  
National Board of Health and Welfare, Sweden.
- 2013-2020 Member of the Swedish National Guidelines for Breast Cancer
- 2013-present Member of the Swedish Breast Cancer Group (SweBCG)
- 2013-2018 President of the National Educational Committee in Breast Cancer Surgery
- 2013-2018 Regional Breast Cancer Process Manager. Regional Cancer Center West, Gothenburg, Sweden.
- 2013-2018 President of the National Educational Committee in Breast Cancer Surgery
- 2011-present Member of the Swedish National Guidelines for Melanoma
- 2011-present Member of the Swedish Melanoma Study Group (SMSG)

---

## ADMINISTRATIVE COMPETENCE AND EXPERIENCE

---

### Learning/formal competence and experience within finance and administration

- 2019-present Research Group Leader, Wallenberg Center for Molecular and Translational Medicine, Gothenburg University, Gothenburg, Sweden
- 2018-2021 Director, Sahlgrenska Breast Center, Sahlgrenska University Hospital
- 2016 Team development course “Utveckling-Grupp-Ledare, UGL kurs”. 5 days.
- 2015 Mandatory course for first-line managers at Sahlgrenska University Hospital spanning over a year. The course including lectures and seminars concerning health care laws, economy systems, budget, employer liabilities, environmental plans, team and personal development, rehabilitation plans etc.
- 2015-2021 Head, Breast and Melanoma Surgery, Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden
- 2002-2006 Chief Executive Office, Scimus AB

---

## INTERACTION WITH THE COMMUNITY

---

### Popular science and community

- 2022 Invited as a lecturer discussing Medical Products at Politikerveckan in Almedalen, Visby, Sweden. 2022-07-04
- 2022 Invited as a lecturer to the Swedish Parliament discussing the Swedish Cancer Plan. “Offentlig utfrågning i Socialutskottet”, Stockholm, Sweden. 2022-06-02
- 2020 Arranged Race-for-the-cure together with Göteborgsvarvet. An international effort in gathering money for breast cancer research and to reduce inequalities in breast cancer treatment in Europe. <https://www.raceforthecure.eu/sv>
- 2020 Leading a symposium in the Swedish Parliament “Ett seminarium om hur Sverige blev bäst och hoten mot bröstcancervården idag” together with the Minister for Health and Social Affairs, Lena Hallengren. 2020-03-11.
- 2020 Lecture for patients in “Bröstcancerföreningen Johanna” concerning breast cancer. 2020-02-03.
- 2019 Lecture for patients in “Bröstcancerföreningen Johanna” concerning breast cancer surgery. 2019-10-04.
- 2019 Lecture for patients in “Bröstcancerföreningen Johanna” concerning breast cancer. 2019-02-21.

### Popular scientific output

- 2019 Lindqvist Bagge, A-S., Lekander, M., Ny, L., **Olofsson Bagge, R.** & Fahlke, C. Förmedla hälsopsykologisk kunskap utan att öka hälsorelaterad oro. *Psykologtidningen*, 2019 (3): 36-37.
- 2019 Lindqvist Bagge, A-S., Lekander, M., Ny, L., **Olofsson Bagge, R.** & Fahlke, C. Ökad hälsomedvetenhet kan öka människors hälsoångest? *Läkartidningen*, 2019;116

## Media coverage

- 2022 Sahlgreńska Liv. 2022-02-09 Interview. "Möt sju av sjukhusets kliniska forskare".
- 2021 Swedish Radio (SR P4). 2021-10-15 Interview. "Köerna till mammografin har ökat kraftigt".
- 2021 Sahlgreńska Liv. 2021-08-26 Interview. "Sveriges finaste kirurgpris till Roger Olofsson Bagge".
- 2021 Sahlgreńska Liv. 2021-04-11 Interview. "Teamet blir länken mellan patienten och forskningen".
- 2021 Sahlgreńska Liv. 2021-03-10 Interview. "Nordens första certifierade Bröstcentrum finns på Sahlgreńska Universitetssjukhuset".
- 2021 Sahlgreńska Liv. 2021-02-22 Interview. "Läkarna som fick covid berättar: Det jag har sett är ett magnifikt och prestigelöst lagarbete".
- 2021 Swedish Radio (SR P4). 2021-02-07 Interview. "Överläkaren Roger blev själv covid-patient".
- 2021 Newspaper Göteborgs-Posten. 2021-10-14 News article "Extremt lång kö till utredning om bröstcancer på Sahlgreńska".
- 2020 Biobank Sverige. 2020-10-30 Interview "Roger Olofsson Bagge: Patientnära studier för bättre cancerbehandlingar"
- 2019 Swedish television (SVT1). National news commenting on Sahlgreńska Breast Center.
- 2019 Swedish Radio (SR P1). National news commenting on Sahlgreńska Breast Center.
- 2019 Newspaper Göteborgs-Posten. 2019-10-19 News article "Symtomen pekade mot cancer – fick remiss till sjukgymnast".
- 2019 Newspaper Göteborgs-Posten. 2019-08-16 News article "Längst väntan för bröstcancerpatienter i Västsverige".
- 2019 Newspaper Göteborgs-Posten. 2019-04-25 News article "Opererades för bröstcancer – kallades inte på sista efterkontrollen".
- 2019 Newspaper Göteborgs-Posten. 2019-02-07 News article "Sahlgreńska storsatsar på bröstcancervården".
- 2018 Newspaper Göteborgs-Posten. 2018-05-01 News article "Här görs världsunika canceroperationer". News article describing me new surgical technique of minimal-invasive ILP.
- 2018 The Sahlgreńska pod "Roger Olofsson Bagge om unika canceroperationer och vikten av forskning" <https://sahlgrenskapodden.podbean.com>
- 2017 Interview. Svensk Onkologi 2017:3, page 17. "Nygammal metod öppnar nya behandlingsmöjligheter för ovanliga tumörer."
- 2017 Swedish radio (SR P4). News concerning ILP "Få biverkningar vid unik cancerbehandling på SU"
- 2017 Swedish television (SVT1). News concerning "Få biverkningar vid unik cancerbehandling på SU"
- 2015 Swedish radio (SR P3). 2015-03-28 Interview in the program "Institutet", Sveriges Radio P3, "Värme hjälper till att döda cancertumörer".
- 2014 Newspaper Göteborgs-Posten. 2014-04-06 News article "Ny medicin ger cancersjuka hopp"

## Social media

Active on Twitter @OlofssonBagge where I mainly tweet about research and news in breast cancer and melanoma. In 2019 I was one of the most influential tweeters on the European Society of Surgical Oncology meeting, discussed in a manuscript *Kjetil Søreide et al "Tweeting the meeting: Quantitative and qualitative twitter activity during the 38th ESSO conference" European Journal of Surgical Oncology, Volume 45, Issue 2, 2019, Pages 284-289.*

## Innovation and Entrepreneurship

### Scimus AB

In 1998 me and two friends started the computer company MainFrame Solutions AB, that later changed name to Scimus AB. It was a small company working within the energy and IT sector in Sweden and Iceland. I was the Chief Executive Officer (CEO) and led negotiations with e.g. the Icelandic Ministry

of Fishing, where we developed a computer program to make the Icelandic fishing industry more energy efficient. We had all the major Swedish energy companies as clients (Vattenfall, Sydkraft, Fortum etc), where we developed web-based applications for their private customers to use to make their houses more energy efficient. I was at this time fluent in several programming languages and developed several computer programs. My initial plan was to continue working within IT, but after my military service I chose to become a physician instead, and later I sold my part of the company.

### **SATMEG Ventures**

2020 I was a founding partner of the company SATMEG Ventures AB, where I have 10% of the shares. The company's founders have expertise in preclinical and clinical research in cancer. The object of the company's operations is to develop new treatments for solid tumours, to own and manage intangible assets, shares and participations in subsidiaries and associated companies. The company owns parts of patents in which I am a partner.

### **Sahlgrenska International Care**

Through Sahlgrenska International Care (SIC), treatment with isolated limb perfusion is offered to international patients. I am the responsible person for these treatments and have together with SIC setup the treatment including information and contacts with international patients.

<https://www.sahlgrenska.se/en/sahlgrenska-international-care/medical-care/treatments/>

### **Patents**

Development of epigenetic therapies for melanoma together with RedGlead AB and SARomics Biostructures AB. It exploits the therapeutic vulnerabilities of tumours driven by BET bromodomain protein-mediated transcriptional elongation. Novel small molecule inhibitors have been developed which has in vitro and in vivo efficacy. GU Ventures, SLU Holding, Vasa Angels, Red Glead and SARomics have agreed to invest. SATMEG Ventures, where I own 10%, owns a substantial part of the patent.